

**BCG vaccine**

## Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against tuberculosis

**Ebola vaccine**

## Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against certain single viral diseases

**Japanese encephalitis vaccine**

## Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

## Indications

Need for immunization against certain single viral diseases

**Medicines for COVID-19**

## Section

[Medicines for COVID-19](#)

Refer to WHO living guidelines

## Indications

COVID-19

**Abacavir**

## Section

[Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)  
Oral > Solid: 300 mg tablet (as sulfate)

## Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

**Abacavir + dolutegravir + lamivudine**

## Section

[Fixed-dose combinations of antiretrovirals](#)

Oral > Solid > tablet: 60 mg (as sulfate) + 5 mg + 30 mg (dispersible, scored)

## Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abacavir + lamivudine + lopinavir + ritonavir

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Abemaciclib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

## Abiraterone

### Section

Hormones and antihormones

Oral > Solid: 250 mg; 500 mg

### Indications

Malignant neoplasms of prostate

## Acamprosate calcium

### Section

Medicines for alcohol use disorders

Oral > Solid > tablet: 333 mg

### Indications

Disorders due to use of alcohol

## Acenocoumarol

| Section                         | Indications                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines affecting coagulation | <p>Therapeutic equivalent to warfarin for</p> <div>Other specified diseases of arteries or arterioles</div> <p>Therapeutic equivalent to warfarin for</p> <div>Venous thromboembolism</div> <p>Therapeutic equivalent to warfarin for</p> <div>Cerebral ischaemic stroke due to embolic occlusion</div> <p>Therapeutic equivalent to warfarin for</p> <div>Atrial fibrillation</div> |

## Acetazolamide

| Section                                                                                    | Indications                            |
|--------------------------------------------------------------------------------------------|----------------------------------------|
| Ophthalmological preparations > Miotics and antiglaucoma medicines<br>Oral > Solid: 250 mg | <div>Primary open-angle glaucoma</div> |

## Acetic acid

| Section                                                                       | Indications                                    |
|-------------------------------------------------------------------------------|------------------------------------------------|
| Ear, nose and throat medicines [c]<br>Local > Otological > drops: 2% solution | <div>Infectious diseases of external ear</div> |

## Acetylcysteine

| Section                                                                                                                                                         | Indications                                                                                                                                                                       |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Antidotes and other substances used in poisonings > Specific<br>Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule<br>Oral > Liquid: 10%; 20% | <div>Acute or subacute hepatic failure</div> <div>Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs</div> |

## Acetylsalicylic acid

| Section                                                                                                                                                                                  | Indications                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Anti-platelet medicines<br>Oral > Solid: 100 mg                                                                                                                                          | Acute myocardial infarction<br>Cerebral ischaemic stroke                                                                         |
| Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)<br>Oral > Solid: 100 to 500 mg<br>Local > Rectal > Suppository: 50 to 150 mg                                          | Pain                                                                                                                             |
| Medicines for acute migraine attacks<br>Oral > Solid: 300 to 500 mg                                                                                                                      | Migraine                                                                                                                         |
| Medicines for juvenile joint diseases<br>Local > Rectal > Suppository: 150 mg; 300 mg<br>Oral > Solid > dispersible tablet: 75 mg; 300 mg; 500 mg<br>Oral > Solid > tablet: 75 to 500 mg | Acute rheumatic fever without mention of heart involvement<br>Mucocutaneous lymph node syndrome<br>Juvenile idiopathic arthritis |

## Acetylsalicylic acid + atorvastatin + ramipril

| Section                                                                                                                                                                                                                                                   | Indications                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease<br>Oral > Solid > tablet: 100 mg + 20 mg + 2.5 mg; 100 mg + 20 mg + 5 mg; 100 mg + 20 mg + 10 mg; 100 mg + 40 mg + 2.5 mg; 100 mg + 40 mg + 5 mg; 100 mg + 40 mg + 10 mg | Atherosclerotic chronic arterial occlusive disease<br>Chronic ischaemic heart disease<br>Cerebral ischaemic stroke |

## Acetylsalicylic acid + simvastatin + ramipril + atenolol + hydrochlorothiazide

| Section                                                                                                                                            | Indications                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease<br>Oral > Solid > tablet: 100 mg + 20 mg + 5 mg + 50 mg + 12.5 mg | Atherosclerotic chronic arterial occlusive disease<br>Chronic ischaemic heart disease<br>Cerebral ischaemic stroke |

## Aciclovir

### Section

[Ophthalmological preparations > Anti-infective agents](#)

Local > Ophthalmological > Ointment: 3% w/w

[Antiherpes medicines](#)

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

[Medicines for viral central nervous system infections](#)

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet

Parenteral > General injections > IV: 250 mg in vial powder for solution for infusion (as sodium dihydrate); 25 mg per mL in vial solution for infusion (as sodium)

### Indications

Herpes simplex keratitis

Herpes simplex infections

Zoster

Varicella

Herpes simplex infections

Zoster

Varicella

## Acclidinium

### Section

[Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

### Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

## Activated charcoal

### Section

[Antidotes and other substances used in poisonings > Non-specific](#)

Oral > Liquid: 50 mg granules for oral suspension

### Indications

Unspecified injury, poisoning or certain other consequences of external causes

## Adalimumab

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Indications                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| <a href="#">Immunomodulators for non-malignant disease</a><br>Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL                                                                                                                                                                                                                                                                                                                                                           | <a href="#">Axial spondyloarthritis</a><br><a href="#">Crohn disease site</a><br><a href="#">Rheumatoid arthritis</a> |
| <a href="#">Medicines for juvenile joint diseases</a><br>Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL                                                                                                                                                                                                                                                                                                                                                                | <a href="#">Juvenile idiopathic arthritis</a>                                                                         |
| <a href="#">Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</a><br>Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen. | <a href="#">Psoriasis of unspecified type</a>                                                                         |

## Afatinib

| Section                            | Indications                                                                                                                        |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Targeted therapies</a> | Therapeutic equivalent to <a href="#">erlotinib</a> for<br><a href="#">Other specified malignant neoplasms of bronchus or lung</a> |

## Albendazole

| Section                                                                                                     | Indications                                                                                                                                                                                        |
|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Intestinal anthelmintics</a><br>Oral > Solid > tablet: 400 mg (chewable, scored)                | <a href="#">Echinococcosis</a><br><a href="#">Enterobiasis</a><br><a href="#">Trichuriasis</a><br><a href="#">Hookworm diseases</a><br><a href="#">Cysticercosis</a><br><a href="#">Ascariasis</a> |
| <a href="#">Cysticidal medicines</a><br>Oral > Solid > tablet: 400 mg (chewable, scored); 200 mg (chewable) | <a href="#">Other specified echinococcosis</a><br><a href="#">Cysticercosis of central nervous system</a>                                                                                          |
| <a href="#">Antifilarials</a><br>Oral > Solid > tablet: 400 mg (chewable, scored)                           | <a href="#">Lymphatic filariasis</a>                                                                                                                                                               |

## Alcohol based hand rub

| Section                                                                                 | Indications       |
|-----------------------------------------------------------------------------------------|-------------------|
| Disinfectants<br>Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol | Denatured alcohol |

## Alcuronium

| Section                                                                                                                                                         | Indications      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Muscle relaxants (peripherally-acting) and cholinesterase inhibitors<br>Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride) | Muscle relaxants |

## Alfacalcidol

| Section                                                                                                  | Indications                                                                                 |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Medicines for endocrine disorders<br>Oral > Liquid: 2 µg per mL<br>Oral > Solid > capsule: 0.25 µg; 1 µg | Chronic kidney disease, stage unspecified<br>Disorders of vitamin D metabolism or transport |

## All-trans retinoic acid

| Section                                           | Indications                                                  |
|---------------------------------------------------|--------------------------------------------------------------|
| Targeted therapies<br>Oral > Solid: 10 mg capsule | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Allopurinol

| Section                                                                                                                               | Indications           |
|---------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Medicines used to treat gout<br>Oral > Solid: 100 mg                                                                                  | Gout                  |
| Supportive medicines<br>Parenteral > General injections > IV: 500 mg (as sodium) powder for injection<br>Oral > Solid: 100 mg; 300 mg | Tumour lysis syndrome |

## Alprostadil (prostaglandin E1)

| Section                                                                                                     | Indications                                                                  |
|-------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Medicines administered to the neonate [c]<br>Parenteral > General injections > IV: 0.5 mg per mL in alcohol | Other specified congenital anomaly of great arteries including arterial duct |

## Alteplase

### Section

#### Thrombolytic medicines

Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection

### Indications

Cerebral ischaemic stroke

## Amidotrizoate

### Section

#### Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)

### Indications

Amidotrizoate

## Amikacin

### Section

#### Ophthalmological preparations > Anti-infective agents

#### Access group antibiotics

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

### Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

#### First choice

Neutropenia (high-risk)

co-prescribed with [cefotaxime](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [cefotaxime](#)

Acute pyelonephritis (severe)

co-prescribed with [ceftriaxone](#)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [ceftriaxone](#)

Acute pyelonephritis (severe)

#### Second choice

co-prescribed with [cloxacillin](#)

Sepsis without septic shock

#### Antituberculosis medicines

Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Multi-drug resistant *Mycobacterium tuberculosis*

## Amiloride

| Section                                         | Indications                          |
|-------------------------------------------------|--------------------------------------|
| Diuretics<br>Oral > Solid: 5 mg (hydrochloride) | <div>Oedema</div> <div>Ascites</div> |

## Amiodarone

| Section                                                                                                                                                                                             | Indications                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Antiarrhythmic medicines<br>Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)<br>Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride) | <div>Cardiac arrhythmia</div> |

## Amitriptyline

| Section                                                                                                                               | Indications                     |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Medicines for depressive disorders<br>Oral > Solid: 25 mg; 75 mg                                                                      | <div>Depressive disorders</div> |
| Medicines for migraine prophylaxis<br>Oral > Solid > tablet: 25 mg                                                                    | <div>Migraine</div>             |
| Medicines for other common symptoms in palliative care<br>Oral > Liquid: 25 mg per 5 mL<br>Oral > Solid > tablet: 25 mg; 10 mg; 75 mg | <div>Palliative care</div>      |

## Amlodipine

| Section                                                                             | Indications                       |
|-------------------------------------------------------------------------------------|-----------------------------------|
| Antihypertensive medicines<br>Oral > Solid: 5 mg (as maleate, mesylate or besylate) | <div>Essential hypertension</div> |

## Amodiaquine

| Section                                                                                                                         | Indications                                                                                |
|---------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Antimalarial medicines > Medicines for curative treatment<br>Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride) | <div>Malaria due to Plasmodium falciparum</div> <div>Malaria due to Plasmodium vivax</div> |

## Amodiaquine - sulfadoxine + pyrimethamine

### Section

[Antimalarial medicines](#) > [Medicines for chemoprevention](#)

Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package

### Indications

Malaria

## Amoxicillin

### Section

#### Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)

#### Medicines for bacterial central nervous system infections

Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid

Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection

Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate)

Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate)

### Indications

#### First choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Acute malnutrition in infants, children or adolescents (uncomplicated) [children]

Acute malnutrition in infants, children or adolescents (complicated) [children]

Acute pharyngitis

Chronic obstructive pulmonary disease with acute exacerbation

Periapical abscess without sinus

Acute otitis media

Acute sinusitis

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with gentamicin

Sepsis without septic shock

#### Second choice

Bacterial meningitis

#### Other indications

Infectious cystitis

Bacterial infection of unspecified site

#### Second choice

Bacterial meningitis

## Amoxicillin + clavulanic acid

### Section

#### Access group antibiotics

Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection

Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

#### Antituberculosis medicines

Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid

Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)

Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

### Indications

#### First choice

Peritoneal abscess (mild-moderate)

Neutropenia (low-risk)

Other specified pneumonia (Hospital-acquired pneumonia)

Infectious cystitis

Chronic obstructive pulmonary disease with acute exacerbation

Peritonitis (mild-moderate)

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choice

Osteomyelitis or osteitis

Acute otitis media

Other specified prophylactic measures

Bacterial infection of joint

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Other indications

Bacterial infection of unspecified site

Multi-drug resistant Mycobacterium tuberculosis

## Amphotericin B

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

#### Antileishmaniasis medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex); 50 mg in vial powder for injection (as sodium deoxycholate)

### Indications

Blastomycosis

Cryptococcosis

Candidosis

Coccidioidomycosis

Histoplasmosis

Sporotrichosis

Aspergillosis

Visceral leishmaniasis

## Ampicillin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension

Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)

### Indications

#### First choice

co-prescribed with [gentamicin](#)

[Peritoneal abscess \(severe\)](#)

co-prescribed with [gentamicin](#)

[Sepsis without septic shock](#)

co-prescribed with [gentamicin](#)

[Peritoneal abscess \(mild-moderate\)](#)

co-prescribed with [gentamicin](#)

[Peritonitis \(severe\)](#)

co-prescribed with [gentamicin](#)

[Acute malnutrition in infants, children or adolescents \(complicated\) \[children\]](#)

co-prescribed with [gentamicin](#)

[Peritonitis \(mild-moderate\)](#)

co-prescribed with [gentamicin](#)

[Bacterial pneumonia \(Community-acquired pneumonia - severe\) \[children\]](#)

#### Second choice

[Bacterial meningitis](#)

#### Other indications

[Bacterial infection of unspecified site](#)

#### Second choice

[Bacterial meningitis](#)

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection

## Anakinra

### Section

#### Medicines for juvenile joint diseases

Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe

### Indications

[Juvenile systemic arthritis](#)

## Anastrozole

### Section

#### Hormones and antihormones

Oral > Solid: 1 mg tablet

### Indications

[Other specified malignant neoplasms of breast](#)

[Malignant neoplasms of breast](#)

## Anidulafungin

### Section

Antifungal medicines

### Indications

Therapeutic equivalent to [micafungin](#) for

Systemic or invasive candidosis

## Ansuvimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 400 mg powder for injection

### Indications

Ebola virus disease

## Anti-D immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IV: 250 µg in single-dose vial

Parenteral > General injections > IM: 250 µg in single-dose vial

### Indications

Rh incompatibility reaction

Maternal care for red cell antibodies

## Anti-rabies immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IM: 150 IU per mL in vial

Parenteral > Locoregional injections > Other: 150 IU per mL in vial

### Indications

Rabies

## Anti-rabies virus monoclonal antibodies

### Section

[Immunologicals](#) > [Sera, immunoglobulins and monoclonal antibodies](#)

Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)

### Indications

Rabies

## Anti-tetanus immunoglobulin

### Section

Human immunoglobulins

Parenteral > General injections > IM: 500 IU in vial

### Indications

Tetanus

## Antirabies hyperimmune serum

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule

### Indications

Rabies

## Antivenom immunoglobulin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
Parenteral > General injections > IV:

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Antivenom sera

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
Parenteral > General injections > IV:

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Apixaban

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

## Aprepitant

### Section

Antiemetic medicines  
Oral > Liquid: 125 mg powder for oral suspension (in sachet)  
Oral > Solid > capsule: 80 mg; 125 mg; 165 mg

### Indications

Nausea or vomiting

## Aripiprazole

### Section

Medicines for psychotic disorders  
Parenteral > General injections > IM: 300 mg powder and solvent for suspension; 400 mg powder and solvent for suspension

### Indications

Therapeutic equivalent to [risperidone](#) for

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

## Arpraziquantel

### Section

Antischistosomes and other antitrepatode medicines

Oral > Solid > dispersible tablet: 150 mg

### Indications

Therapeutic equivalent to praziquantel for

Schistosomiasis

## Arsenic trioxide

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 1 mg per mL concentrate for solution

for infusion; 2 mg per mL concentrate for solution for infusion

### Indications

Acute myeloid leukaemia with recurrent genetic abnormalities

## Artemether

### Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IM: 20 mg per mL in 1 mL ampoule (oily injection); 40 mg per mL in 1 mL ampoule (oily injection)

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artemether + lumefantrine

### Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > dispersible tablet: 20 mg + 120 mg

Oral > Solid > tablet: 20 mg + 120 mg

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate

### Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IV: 60 mg in vial powder for injection; 30 mg in vial powder for injection; 120 mg in vial powder for injection

Local > Rectal > Other: 100 mg capsules

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate + amodiaquine

### Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg

Oral > Solid > tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg tablet

### Indications

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium vivax

## Artesunate + mefloquine

### Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 25 mg + 50 mg (as hydrochloride); 100 mg + 200 mg (as hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Artesunate + pyronaridine

### Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 60 mg + 180 mg (tetraphosphate)

Oral > Solid > granules: 20 mg + 60 mg (tetraphosphate)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Artesunate - sulfadoxine + pyrimethamine

### Section

[Antimalarial medicines](#) > [Medicines for curative treatment](#)

Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Ascorbic acid

### Section

[Vitamins and minerals](#)

Oral > Solid: 50 mg

### Indications

Scurvy

## Asparaginase

### Section

[Cytotoxic medicines](#)

Powder for injection: 10 000 IU in vial.

Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Lymphoid leukaemia, not elsewhere classified

## Atazanavir

### Section

[Antiretrovirals](#) > [Protease inhibitors](#)

Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atazanavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Atenolol

### Section

Antianginal medicines

Oral > Solid: 50 mg; 100 mg

Antihypertensive medicines

Oral > Solid: 50 mg; 100 mg

### Indications

Angina pectoris

Essential hypertension

Therapeutic equivalent to [bisoprolol](#) for

Essential hypertension

## Atezolizumab

### Section

Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to [pembrolizumab](#) for

Adenocarcinoma of stomach

Hepatocellular carcinoma of liver

## Atoltivimab + maftivimab + odesivimab

### Section

Medicines for Ebola virus disease

Parenteral > General injections > IV: 241.7 mg + 241.7 mg + 241.7 mg in 14.5 mL vial

### Indications

Ebola virus disease

## Atorvastatin

### Section

Lipid-lowering agents

### Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

## Atorvastatin + perindopril + amlodipine

### Section

Fixed-dose combinations for prevention of atherosclerotic cardiovascular disease

Oral > Solid > tablet: 20 mg + 5 mg + 5 mg; 20 mg + 10 mg + 10 mg; 40 mg + 5 mg + 5 mg; 40 mg + 10 mg + 10 mg

### Indications

Chronic ischaemic heart disease

Atherosclerotic chronic arterial occlusive disease

Cerebral ischaemic stroke

## Atracurium

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL (besylate)

### Indications

Muscle relaxants

Therapeutic equivalent to [vecuronium](#) for

Muscle relaxants

## Atropine

### Section

Diagnostic agents > Ophthalmic medicines

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)

Preoperative medication and sedation for short-term procedures

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate); 400 µg per mL in 1 mL ampoule or vial (sulfate)

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule or vial (sulfate)

### Indications

Therapeutic equivalent to [tropicamide](#) for

Cycloplegic drug

Anterior uveitis

Parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics

Exposure to or harmful effects of undetermined intent of pesticides

## Axicabtagene ciloleucel

### Section

Antineoplastics and supportive medicines

Cell suspension for infusion:  $2 \times 10^6$  anti-CD19 CAR-positive viable T-cells per kg of body weight.

### Indications

Diffuse large B-cell lymphomas

## Axitinib

### Section

#### Targeted therapies

Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

### Indications

Renal cell carcinoma of kidney, except renal pelvis

## Azacitidine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection

### Indications

Myeloid leukaemia

## Azathioprine

### Section

#### Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)

Oral > Liquid: 10 mg per mL

Oral > Solid > tablet: 25 mg; 50 mg (scored)

Oral > Solid > tablet: 50 mg (scored)

#### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid > tablet: 50 mg (scored)

### Indications

Failure or rejection of transplanted organs or tissues

Relapsing-remitting multiple sclerosis

Rheumatoid arthritis, serology unspecified

Psoriatic arthritis

## Azithromycin

### Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1.5% eye drops

Watch group antibiotics

Oral > Liquid: 200 mg per 5 mL (anhydrous) powder for oral liquid

Oral > Solid > dosage form: 250 mg (anhydrous); 500 mg (anhydrous)

### Indications

Trachoma

#### First choice

Chlamydia trachomatis

Typhoid fever

Yaws

Paratyphoid fever

Cholera

Cholera [children]

Trachoma

co-prescribed with ceftriaxone

Gonococcal infection

#### Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with cefixime

Gonococcal infection

## Aztreonam

### Section

Reserve group antibiotics

Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified bacterial diseases

## Baclofen

### Section

Medicines for cerebral palsy

Oral > Liquid: 10 mg per 5 mL

Parenteral > Locoregional injections > Intrathecal: 500 µg per mL in ampoule

Oral > Solid > tablet: 10 mg

### Indications

Spastic cerebral palsy

## Barium sulfate

### Section

Diagnostic agents > Radiocontrast media  
Oral > Liquid: Aqueous suspension

### Indications

Barium sulfate with suspending agents

## Beclometasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease  
Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)

### Indications

Asthma

Therapeutic equivalent to [budesonide](#) for

Asthma

## Beclometasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide](#) + [formoterol](#) for

Asthma

## Bedaquiline

### Section

Antituberculosis medicines  
Oral > Solid > tablet: 100 mg tablet; 20 mg tablet

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Beinaglutide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

## Bendamustine

### Section

Cytotoxic medicines  
Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

### Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Benzathine benzylpenicillin

### Section

[Access group antibiotics](#)

Parenteral > General injections > IM: 1.2 million IU in vial ( $\approx$  900 mg) powder for injection; 2.4 million IU in vial ( $\approx$  1.8 g) powder for injection

### Indications

#### First choice

[Syphilis](#)

[Congenital syphilis \[children\]](#)

#### Other indications

[Bacterial infection of unspecified site](#)

## Benznidazole

### Section

[American trypanosomiasis](#)

Oral > Solid > tablet: 100 mg (scored); 50 mg (scored); 12.5 mg

### Indications

[Chagas disease](#)

## Benzoic acid + salicylic acid

### Section

[Dermatological medicines > Antifungal medicines](#)

Local > Topical > Cream: 6% + 3%

Local > Topical > Ointment: 6% + 3%

### Indications

[Fungal infection of the skin](#)

## Benzoyl peroxide

### Section

[Dermatological medicines > Medicines affecting skin differentiation and proliferation](#)

Local > Topical > Cream: 5%

Local > Topical > Lotion: 5%

### Indications

[Acne](#)

## Benzyl benzoate

### Section

[Dermatological medicines > Scabicides and pediculicides](#)

Local > Topical > Lotion: 25%

### Indications

[Pthiriasis](#)

[Pediculosis corporis](#)

[Pediculosis capitis](#)

[Scabies](#)

## Benzylpenicillin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)

### Indications

#### First choice

Congenital syphilis [children]

Syphilis

co-prescribed with gentamicin

Sepsis without septic shock

co-prescribed with gentamicin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with gentamicin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

#### Second choice

Bacterial meningitis

#### Other indications

Bacterial infection of unspecified site

#### Second choice

Bacterial meningitis

## Beractant

### Section

#### Medicines administered to the neonate [c]

Respiratory > Suspension: 25 mg per mL for intratracheal instillation

### Indications

Respiratory distress syndrome of newborn

## Betamethasone

### Section

#### Dermatological medicines > Anti-inflammatory and antipruritic medicines

Local > Topical > Cream: 0.1% (as valerate)

Local > Topical > Ointment: 0.1% (as valerate)

### Indications

Pruritus due to skin disorder

Psoriasis of unspecified type

Dermatitis or eczema

Lichen planus

## Bevacizumab

### Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

Parenteral > Locoregional injections > Intravitreal: 25 mg per mL

Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

### Indications

Age related macular degeneration

Hepatocellular carcinoma of liver

## Bicalutamide

### Section

Hormones and antihormones

Oral > Solid: 50 mg

### Indications

Malignant neoplasms of prostate

## Binimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [trametinib](#) for

Other specified melanoma of skin

## Biperiden

### Section

Medicines for parkinsonism

Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)

Oral > Solid: 2 mg tablet (hydrochloride)

### Indications

Parkinson disease

## Bisacodyl

### Section

Laxatives

### Indications

Therapeutic equivalent to [senna](#) for

Constipation

## Bisoprolol

| Section                                                           | Indications            |
|-------------------------------------------------------------------|------------------------|
| Antianginal medicines<br>Oral > Solid: 1.25 mg; 5 mg              | Angina pectoris        |
| Medicines used in heart failure<br>Oral > Solid: 1.25 mg; 5 mg    | Heart failure          |
| Antihypertensive medicines<br>Oral > Solid: 1.25 mg; 5 mg         | Essential hypertension |
| Antiarrhythmic medicines<br>Oral > Solid: 1.25 mg; 5 mg           | Cardiac arrhythmia     |
| Medicines for migraine prophylaxis<br>Oral > Solid: 1.25 mg; 5 mg | Migraine               |

## Bleomycin

| Section                                                                                             | Indications                                                         |
|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate) | Germ cell tumour of testis                                          |
|                                                                                                     | Kaposi sarcoma of unspecified primary site                          |
|                                                                                                     | Hodgkin lymphoma                                                    |
|                                                                                                     | Other specified malignant neoplasms of the ovary                    |
|                                                                                                     | Unspecified malignant neoplasms of ill-defined or unspecified sites |

## Blinatumomab

| Section                                                                                  | Indications                                                     |
|------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Immunomodulators<br>Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial | B lymphoblastic leukaemia or lymphoma, not elsewhere classified |

## Bortezomib

| Section                                                                                                  | Indications         |
|----------------------------------------------------------------------------------------------------------|---------------------|
| Targeted therapies<br>Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection | Plasma cell myeloma |

## Brexpiprazole

### Section

Medicines for depressive disorders

Oral > Solid > tablet: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg

### Indications

Depressive disorders

## Bromocriptine

### Section

Antiseizure medicines

Oral > Solid: 2.5 mg; 5 mg

Medicines for disorders of the pituitary hormone system

### Indications

Parkinson disease

Therapeutic equivalent to [cabergoline](#) for

Other specified benign neoplasm of endocrine glands

## Budesonide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 100 µg per actuation in dry powder inhaler; 200 µg per actuation in dry powder inhaler

Respiratory > Inhalation > suspension: 100 µg per actuation in pressurized metered dose inhaler; 200 µg per actuation in pressurized metered dose inhaler

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 32 µg per actuation; 64 µg per actuation

### Indications

Asthma

Allergic rhinitis

## Budesonide + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler; 200 µg + 6 µg per dose actuation in dry powder inhaler

### Indications

Asthma

## Budesonide + salmeterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide + formoterol](#) for

Asthma

## Bumetanide

| Section                         | Indications                                                                                                                                                                          |
|---------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines used in heart failure | Therapeutic equivalent to <a href="#">furosemide</a> for<br><a href="#">Heart failure</a>                                                                                            |
| Diuretics                       | Therapeutic equivalent to <a href="#">furosemide</a> for<br><a href="#">Anuria or oliguria</a><br>Therapeutic equivalent to <a href="#">furosemide</a> for<br><a href="#">Oedema</a> |

## Bupivacaine

| Section                                                                                                                                                                                                                                   | Indications                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Local anaesthetics<br>Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 8% glucose solution<br>Parenteral > General injections > unspecified: 0.25% (hydrochloride); 0.5% (hydrochloride) | <a href="#">Local anaesthetics</a> |

## Buprenorphine

| Section                            | Indications                                                                                  |
|------------------------------------|----------------------------------------------------------------------------------------------|
| Medicines for opioid use disorders | Therapeutic equivalent to <a href="#">methadone</a> for<br><a href="#">Opioid dependence</a> |

## Bupropion

| Section                                                                                        | Indications                         |
|------------------------------------------------------------------------------------------------|-------------------------------------|
| Medicines for nicotine use disorders<br>Oral > Solid: 150 mg sustained-release (hydrochloride) | <a href="#">Nicotine dependence</a> |

## C1 esterase inhibitor

| Section                                                                                               | Indications                           |
|-------------------------------------------------------------------------------------------------------|---------------------------------------|
| Plasma-derived medicines<br>Parenteral > General injections > IV: 500 IU in vial powder for injection | <a href="#">Hereditary angioedema</a> |

## Cabergoline

| Section                                                                                        | Indications                                         |
|------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Medicines for disorders of the pituitary hormone system<br>Oral > Solid > tablet: 0.5 mg; 1 mg | Other specified benign neoplasm of endocrine glands |
| Antiseizure medicines<br>Oral > Solid > tablet: 0.5 mg                                         | Parkinson disease                                   |

## Caffeine citrate

| Section                                                                                                                                                                                                              | Indications       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Medicines administered to the neonate [c]<br>Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)<br>Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL) | Apnoea of newborn |

## Calamine

| Section                                                                                              | Indications |
|------------------------------------------------------------------------------------------------------|-------------|
| Dermatological medicines > Anti-inflammatory and antipruritic medicines<br>Local > Topical > Lotion: | Pruritus    |

## Calcipotriol

| Section                                                                                                                                                                                                                                         | Indications                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>Local > Topical > Cream: 50 µg per mL (0.005%)<br>Local > Topical > Lotion: 50 µg per mL (0.005%)<br>Local > Topical > Ointment: 50 µg per mL (0.005%) | Psoriasis of unspecified type |

## Calcitriol

| Section                                                                               | Indications                                                                                 |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| Dermatological medicines > Medicines affecting skin differentiation and proliferation | Therapeutic equivalent to calcipotriol for<br>Psoriasis of unspecified type                 |
| Medicines for endocrine disorders<br>Oral > Solid > capsule: 0.25 µg; 0.5 µg          | Chronic kidney disease, stage unspecified<br>Disorders of vitamin D metabolism or transport |

## Calcium

### Section

Vitamins and minerals

Oral > Solid: 500 mg (elemental calcium)

### Indications

Calcium deficiency

## Calcium folinate (leucovorin calcium)

### Section

Cytotoxic medicines

Oral > Solid: 15 mg tablet

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule

Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant trophoblastic neoplasms of placenta

Osteosarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of rectum

Malignant neoplasms of colon

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasm metastasis in large intestine

## Calcium gluconate

### Section

Vitamins and minerals

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule or vial (10%)

### Indications

Tetany due to acute calcium deficiency

Hypermagnesaemia

## Canagliflozin

### Section

Oral hypoglycaemic agents

### Indications

Therapeutic equivalent to empagliflozin for

Type 2 diabetes mellitus

## Capecitabine

### Section

Cytotoxic medicines

Oral > Solid > tablet: 150 mg; 500 mg

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of rectum

Malignant neoplasms of colon

## Capreomycin

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg powder for injection (vial)

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Captopril

### Section

Medicines used in heart failure

Oral > Solid: 25 mg

### Indications

Heart failure

## Carbachol

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

### Indications

Therapeutic equivalent to pilocarpine for

Acute angle closure with pupillary block

Therapeutic equivalent to pilocarpine for

Ocular hypertension

Therapeutic equivalent to pilocarpine for

Primary open-angle glaucoma

## Carbamazepine

### Section

#### Medicines for bipolar disorders

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 400 mg

#### Antiseizure medicines

Oral > Liquid: 100 mg per 5 mL

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

#### Medicines for neurological disorders

Oral > Liquid: 100 mg per 5 mL

Oral > Solid > tablet: 100 mg (scored); 200 mg (scored); 100 mg (chewable); 200 mg (chewable); 400 mg (scored)

Oral > Solid > capsule: 100 mg (extended-release); 200 mg (extended-release); 300 mg (extended-release)

### Indications

Bipolar or related disorders

Epilepsy or seizures

Trigeminal neuralgia

## Carbetocin

### Section

#### Uterotonics

Parenteral > General injections > IV: 100 µg per mL (heat stable)

### Indications

Postpartum haemorrhage

## Carbimazole

### Section

#### Thyroid hormones and antithyroid medicines

### Indications

Therapeutic equivalent to [methimazole](#) for

Thyrotoxicosis

## Carboplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### Indications

Other specified gliomas of brain

Other specified carcinomas of ovary

Retinoblastoma

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Malignant neoplasms of kidney, except renal pelvis

Malignant neoplasms of breast

Osteosarcoma of bone and articular cartilage of unspecified sites

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx

Malignant neoplasms of hypopharynx

Malignant neoplasms of nasopharynx

Malignant neoplasms of oropharynx

Malignant neoplasms of cervix uteri

## Carmellose

### Section

#### Ophthalmological preparations

### Indications

Therapeutic equivalent to hypromellose for

Keratoconjunctivitis sicca

## Carvedilol

| Section                         | Indications                                                        |
|---------------------------------|--------------------------------------------------------------------|
| Antianginal medicines           | Therapeutic equivalent to bisoprolol for<br>Angina pectoris        |
| Medicines used in heart failure | Therapeutic equivalent to bisoprolol for<br>Heart failure          |
| Antihypertensive medicines      | Therapeutic equivalent to bisoprolol for<br>Essential hypertension |
| Antiarrhythmic medicines        | Therapeutic equivalent to bisoprolol for<br>Cardiac arrhythmia     |

## Caspofungin

| Section              | Indications                                                                 |
|----------------------|-----------------------------------------------------------------------------|
| Antifungal medicines | Therapeutic equivalent to micafungin for<br>Systemic or invasive candidosis |

## Cefalexin

| Section                                                                                                                                                                                                                                                                                                                                                 | Indications                                                                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Access group antibiotics</p> <p>Oral &gt; Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid</p> <p>Oral &gt; Solid: 250 mg (as monohydrate)</p> <p>Oral &gt; Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)</p> <p>Oral &gt; Solid &gt; dispersible tablet: 125 mg; 250 mg</p> | <p>First choice</p> <p>Bacterial cellulitis, erysipelas or lymphangitis</p> <p>Second choice</p> <p>Acute pharyngitis</p> <p>Chronic obstructive pulmonary disease with acute exacerbation</p> <p>Other indications</p> <p>Bacterial infection of unspecified site</p> |

## Cefazolin

### Section

#### Access group antibiotics

Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection

### Indications

#### First choice

Other specified prophylactic measures

co-prescribed with metronidazole

Other specified prophylactic measures

#### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

#### Other indications

Surgical site infection

## Cefepime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection

### Indications

Other specified bacterial diseases

## Cefiderocol

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial (as sulfate tosylate) powder for injection

### Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Cefixime

### Section

#### Watch group antibiotics

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)

### Indications

#### Second choice

Infectious gastroenteritis or colitis without specification of infectious agent

co-prescribed with azithromycin

Gonococcal infection

## Cefotaxime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with amikacin

Inflammatory and other diseases of prostate (severe)

co-prescribed with amikacin

Acute pyelonephritis (severe)

co-prescribed with clarithromycin

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with metronidazole

Peritonitis (severe)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

co-prescribed with metronidazole

Peritoneal abscess (severe)

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

#### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

Sepsis without septic shock

#### Other indications

Bacterial infection of unspecified site

#### First choice

Bacterial meningitis

## Ceftaroline

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection

### Indications

Other specified bacterial diseases

## Ceftazidime

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection

### Indications

#### First choice

co-prescribed with [vancomycin](#)

Endophthalmitis

#### Other indications

[Pseudomonas aeruginosa](#) resistant to other antibiotic

## Ceftazidime + avibactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection

### Indications

Carbapenem-resistant [Pseudomonas aeruginosa](#)

Carbapenem resistant Enterobacterales

## Ceftolozane + tazobactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g + 0.5 g powder for injection

### Indications

Carbapenem-resistant [Pseudomonas aeruginosa](#)

## Ceftriaxone

### Section

#### Watch group antibiotics

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)  
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

### Indications

#### First choice

Typhoid fever

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Paratyphoid fever

Other specified pneumonia (Hospital-acquired pneumonia)

Bacterial meningitis

co-prescribed with [amikacin](#)

Acute pyelonephritis (severe)

co-prescribed with [amikacin](#)

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

Parenteral > General injections > unspecified: 2 g in vial; 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)

Inflammatory and other diseases of prostate (severe)

co-prescribed with [azithromycin](#)

Gonococcal infection

co-prescribed with [clarithromycin](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with [metronidazole](#)

Necrotising fasciitis

co-prescribed with [metronidazole](#)

Peritonitis (mild-moderate)

co-prescribed with [metronidazole](#)

Peritonitis (severe)

co-prescribed with [metronidazole](#)

Peritoneal abscess (mild-moderate)

co-prescribed with [metronidazole](#)

Peritoneal abscess (severe)

co-prescribed with [vancomycin](#)

Endophthalmitis

#### Second choice

Bacterial infection of joint

Osteomyelitis or osteitis

Infectious gastroenteritis or colitis without specification of infectious agent

Sepsis without septic shock

Inflammatory and other diseases of prostate (mild to moderate)

Acute pyelonephritis (mild to moderate)

#### Other indications

Bacterial infection of unspecified site

#### First choice

Bacterial meningitis

## Cefuroxime

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection

### Indications

#### Second choice

Other specified prophylactic measures

## Cemiplimab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab for

Other specified malignant neoplasms of bronchus or lung

Therapeutic equivalent to pembrolizumab for

Adenocarcinoma of stomach

Other specified malignant neoplasms of bronchus or lung

## Certolizumab pegol

### Section

#### Immunomodulators for non-malignant disease

#### Medicines for juvenile joint diseases

Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to adalimumab for

Axial spondyloarthritis

Therapeutic equivalent to adalimumab for

Crohn disease site

Therapeutic equivalent to adalimumab for

Rheumatoid arthritis

Therapeutic equivalent to adalimumab for

Juvenile idiopathic arthritis

Therapeutic equivalent to adalimumab for

Psoriasis of unspecified type

## Cetirizine

### Section

#### Antiallergics and medicines used in anaphylaxis

### Indications

Therapeutic equivalent to loratadine for

Allergic or hypersensitivity conditions of unspecified type

## Chlorambucil

### Section

#### Cytotoxic medicines

Oral > Solid: 2 mg tablet

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Chloramphenicol

### Section

#### Access group antibiotics

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

Oral > Liquid: 150 mg per 5 mL (as palmitate)

Oral > Solid: 250 mg capsule

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)

Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection

### Indications

#### Second choice

Bacterial meningitis

#### Other indications

Bacterial infection of unspecified site

#### Second choice

Bacterial meningitis

## Chlorhexidine

### Section

#### Medicines administered to the neonate [c]

Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

#### Antiseptics

Local > Topical > Solution: 5% (digluconate) for dilution

### Indications

Omphalitis of newborn

Chlorhexidine

## Chlorine base compound

### Section

#### Disinfectants

Local > Topical > Powder: 0.1% available chlorine for solution

Local > Topical > Liquid: 0.1% available chlorine for solution

Local > Topical > Solid: 0.1% available chlorine for solution

### Indications

Disinfectant, not elsewhere classified

## Chloroquine

### Section

#### Antimalarial medicines > For chemoprevention

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate)

#### Antimalarial medicines > For curative treatment

Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)

#### Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)

#### Antimalarial medicines > Medicines for curative treatment

Oral > Liquid: 50 mg per 5 mL (base)

Oral > Solid > tablet: 150 mg (base)

#### Antimalarial medicines > Medicines for chemoprevention

Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)

Oral > Solid: 150 mg tablet (as phosphate or sulfate)

#### Antimalarial medicines > Medicines for chemoprophylaxis in travellers

Oral > Liquid: 50 mg per 5 mL (base)

Oral > Solid > tablet: 150 mg (base)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium falciparum*

Rheumatoid arthritis

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium malariae*

Malaria due to *Plasmodium vivax*

Malaria due to *Plasmodium vivax*

## Chlorothiazide

### Section

#### Antihypertensive medicines

Therapeutic equivalent to hydrochlorothiazide for

Essential hypertension

#### Medicines used in heart failure

Therapeutic equivalent to hydrochlorothiazide for

Heart failure

## Chloroxylonol

### Section

#### Disinfectants

Local > Topical > Solution: 4.8%

### Indications

Phenol disinfectant, not elsewhere classified

## Chlorpromazine

### Section

#### Medicines for psychotic disorders

Oral > Liquid: 25 mg per 5 mL (hydrochloride)

Oral > Solid: 100 mg (hydrochloride)

Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)

### Indications

Therapeutic equivalent to **haloperidol** for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

## Chlortalidone

### Section

#### Antihypertensive medicines

#### Medicines used in heart failure

### Indications

Therapeutic equivalent to **hydrochlorothiazide** for

Essential hypertension

Therapeutic equivalent to **hydrochlorothiazide** for

Heart failure

## Chlortetracycline

### Section

#### Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to **tetracycline** for

Other specified conjunctivitis

Therapeutic equivalent to **tetracycline** for

Infectious keratitis

Therapeutic equivalent to **tetracycline** for

Infectious blepharitis

Therapeutic equivalent to **tetracycline** for

Trachoma

## Cholera vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against cholera alone

## Ciclesonide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to budesonide for

Asthma

## Ciclopirox

### Section

Dermatological medicines > Antifungal medicines

Local > Topical > Solution: 80 mg per g (as hydroxypropyl chitosan)

### Indications

Onychomycosis

## Ciclosporin

### Section

Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule  
concentrate for injection

Oral > Liquid: 100 mg per mL

Oral > Solid > capsule: 25 mg

### Indications

Failure or rejection of transplanted organs or tissues

## Cimetidine

### Section

Antiulcer medicines

Oral > Solid: 200 mg

Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule

### Indications

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

## Ciprofloxacin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 mg per mL (as hyclate)

Oral > Liquid: 250 mg per 5 mL (anhydrous)

Oral > Solid: 250 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride); 100 mg (as hydrochloride)

Oral > Solid > dosage form: 250 mg (as hydrochloride); 500 mg (as hydrochloride)

#### Ear, nose and throat medicines [c]

Local > Otological > drops: 0.3% (as hydrochloride)

### Indications

#### First choice

Neutropenia (low-risk)

Inflammatory and other diseases of prostate (mild to moderate)

Typhoid fever

Paratyphoid fever

Infectious gastroenteritis or colitis without specification of infectious agent

Acute pyelonephritis (mild to moderate)

#### Second choice

Cholera

Cholera [children]

co-prescribed with metronidazole

Peritoneal abscess (mild-moderate)

co-prescribed with metronidazole

Peritonitis (mild-moderate)

#### Other indications

Bacterial infection of unspecified site

Infectious diseases of external ear

## Cisplatin

| Section                                                                                                                                                                                                                                                               | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection<br><br>Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Other specified gliomas of brain</div> <div>Other specified malignant neoplasms of the ovary</div> <div>Other specified malignant neoplasms of bronchus or lung</div> <div>Malignant neoplasms of nasopharynx</div> <div>Germ cell tumour of testis</div> <div>Osteosarcoma of bone and articular cartilage of unspecified sites</div> <div>Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx</div> <div>Malignant neoplasms of hypopharynx</div> <div>Malignant neoplasms of nasopharynx</div> <div>Malignant neoplasms of oropharynx</div> <div>Malignant neoplasms of cervix uteri</div> |

## Cladribine

| Section                                                                                                                 | Indications                              |
|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial | <div>Langerhans cell histiocytosis</div> |
| <b>Medicines for multiple sclerosis</b><br>Oral > Solid > tablet: 10 mg                                                 | <div>Multiple sclerosis</div>            |

## Clarithromycin

### Section

#### Watch group antibiotics

Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial powder for injection

Oral > Solid > dosage form: 500 mg; 250 mg

Oral > Solid > dosage form: 500 mg

### Indications

#### First choice

co-prescribed with [cefotaxime](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

co-prescribed with [ceftriaxone](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Second choice

Acute pharyngitis

co-prescribed with [amoxicillin + clavulanic acid](#)

Bacterial pneumonia (Community-acquired pneumonia - severe)

#### Other indications

Helicobacter pylori associated gastric ulcer

## Clindamycin

### Section

#### Access group antibiotics

Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride) capsule

Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection

Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)

Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

### Indications

#### First choice

co-prescribed with [piperacillin + tazobactam](#)

Necrotising fasciitis

#### Second choice

Osteomyelitis or osteitis

Bacterial infection of joint

#### Other indications

Bacterial infection of unspecified site

## Clofazimine

### Section

#### Antileprosy medicines

Oral > Solid > dosage form: 100 mg; 50 mg

#### Antituberculosis medicines

Oral > Solid > dosage form: 100 mg; 50 mg

### Indications

Leprosy

Multi-drug resistant Mycobacterium tuberculosis

## Clomifene

### Section

Ovulation inducers

Oral > Solid: 50 mg (citrate)

### Indications

Female infertility without specification whether primary or secondary

## Clomipramine

### Section

Medicines for obsessive compulsive disorders

Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)

### Indications

Obsessive-compulsive disorder

## Clonazepam

### Section

Antiseizure medicines

Oral > Solid: 500 µg

### Indications

Generalised myoclonic seizure

## Clopidogrel

### Section

Anti-platelet medicines

Oral > Solid: 75 mg; 300 mg

### Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

## Clotrimazole

### Section

Antifungal medicines

Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet

### Indications

Vulvovaginal candidosis

## Cloxacillin

### Section

#### Access group antibiotics

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid

Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection

Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid

Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection

Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt)

### Indications

#### First choice

Bacterial infection of joint

Osteomyelitis or osteitis

Bacterial cellulitis, erysipelas or lymphangitis

#### Second choice

co-prescribed with amikacin

Sepsis without septic shock

#### Other indications

Bacterial infection of unspecified site

## Clozapine

### Section

#### Medicines for psychotic disorders

Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg

### Indications

Schizophrenia or other primary psychotic disorders

## Coagulation factor IX complex

### Section

#### Coagulation factors

### Indications

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Coagulation defects, purpura or other haemorrhagic or related conditions

Therapeutic equivalent to coagulation factor IX, plasma-derived for

Haemophilia B

## Coagulation factor IX, plasma-derived

### Section

#### Coagulation factors

Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Coagulation defects, purpura or other haemorrhagic or related conditions

Haemophilia B

## Coagulation factor IX, recombinant

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU per mL in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

### Indications

Haemophilia B

## Coagulation factor VIII, plasma-derived

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection

### Indications

Haemophilia A

## Coagulation factor VIII, recombinant

### Section

#### Coagulation factors

Parenteral > General injections > IV: 250 IU in vial lyophilized powder for solution for injection; 500 IU in vial lyophilized powder for solution for injection; 1000 IU in vial lyophilized powder for solution for injection; 1500 IU in vial lyophilized powder for solution for injection; 2000 IU in vial lyophilized powder for solution for injection; 3000 IU in vial lyophilized powder for solution for injection; 4000 IU in vial lyophilized powder for solution for injection

### Indications

Haemophilia A

## Coal tar

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

### Indications

Psoriasis of unspecified type

## Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Cobimetinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to trametinib for

Other specified melanoma of skin

## Codeine

### Section

Opioid analgesics

Oral > Solid: 30 mg tablet (codeine phosphate)

Antitussives

Oral > Solid: 10 mg tablet (codeine phosphate)

Medicines for diarrhoea

Oral > Solid: 30 mg tablet (codeine phosphate)

### Indications

Pain

Cough

Diarrhoea

## Colchicine

### Section

Medicines used to treat gout

Oral > Solid: 0.5 mg

### Indications

Gout

## Colecalciferol

### Section

Vitamins and minerals

Oral > Liquid: 400 IU per mL

Oral > Solid: 400 IU; 1000 IU

### Indications

Calcium deficiency

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Vitamin D deficiency

Therapeutic equivalent to ergocalciferol for

Calcium deficiency

## Colistin (injection)

### Section

#### Reserve group antibiotics

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium)

Parenteral > General injections > unspecified: 1 million IU in vial (as colistemetate sodium) (equivalent to 34 mg colistin base activity)

### Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Compound sodium lactate solution

### Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral

Parenteral > General injections > IV: injectable solution

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypovolaemic shock

## Condoms

### Section

Barrier methods

-

### Indications

Contact with health services for contraceptive management

## Copper-containing intrauterine device

### Section

Intrauterine devices

-

### Indications

Contact with health services for insertion of contraceptive device

## Crizotinib

### Section

#### Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

## Cryoprecipitate (not pathogen-reduced)

| Section                    | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Blood and blood components | <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Obstetric haemorrhage</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Haemophilia A</p> <p>Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for</p> <p>Von Willebrand disease</p> |

## Cryoprecipitate (pathogen-reduced)

| Section                                                                                                                                                                                  | Indications                                                                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Blood and blood components<br>Injection: frozen liquid in bag or lyophilized powder in vial containing:<br>> 50 IU Factor VIII<br>> 100 IU vWF<br>> 140 mg clottable fibrinogen per unit | <p>Coagulation defects, purpura or other haemorrhagic or related conditions</p> <p>Obstetric haemorrhage</p> <p>Haemophilia A</p> <p>Von Willebrand disease</p> |

## Cyanocobalamin

| Section                    | Indications                             |
|----------------------------|-----------------------------------------|
| Antianaemia medicines<br>. | Anaemias or other erythrocyte disorders |

## Cyclizine

| Section                                                                                                                                                                         | Indications     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| Medicines for other common symptoms in palliative care<br>Parenteral > General injections > unspecified: 50 mg per mL (lactate)<br>Oral > Solid > tablet: 50 mg (hydrochloride) | Palliative care |

## Cyclopentolate

| Section                                    | Indications                                                   |
|--------------------------------------------|---------------------------------------------------------------|
| Diagnostic agents > Ophthalmic medicines   | Therapeutic equivalent to tropicamide for<br>Cycloplegic drug |
| Ophthalmological preparations > Mydriatics | Therapeutic equivalent to atropine for<br>Anterior uveitis    |

## Cyclophosphamide

| Section                                                                                                                                                                                                                                                                                                                              | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Oral > Solid: 25 mg tablet<br>Parenteral > General injections > unspecified: 500 mg in vial powder for injection<br>Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection<br>Oral > Solid > dosage form: 25 mg; 50 mg | Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Other specified malignant neoplasms of breast<br>Malignant trophoblastic neoplasms of placenta<br>Follicular lymphoma<br>Malignant neoplasms of breast<br>Rhabdomyosarcoma primary site<br>Hodgkin lymphoma<br>Plasma cell myeloma<br>Other specified gliomas of brain<br>Malignant neoplasms of kidney, except renal pelvis<br>Ewing sarcoma of bone and articular cartilage of unspecified sites<br>Anaplastic large cell lymphoma, ALK-negative<br>Anaplastic large cell lymphoma, ALK-positive<br>Lymphoid leukaemia, not elsewhere classified<br>Burkitt lymphoma including Burkitt leukaemia<br>Diffuse large B-cell lymphoma, not otherwise specified<br>Chronic lymphocytic leukaemia or small lymphocytic lymphoma |

## Cycloserine

| Section                                                                  | Indications                                     |
|--------------------------------------------------------------------------|-------------------------------------------------|
| Antituberculosis medicines<br>Oral > Solid > dosage form: 250 mg; 125 mg | Multi-drug resistant Mycobacterium tuberculosis |

## Cytarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

Burkitt lymphoma including Burkitt leukaemia

## Cytisine (cytisinicline)

### Section

#### Medicines for nicotine use disorders

Oral > Solid > tablet: 1.5 mg

### Indications

Nicotine dependence

## Dabigatran

### Section

#### Medicines affecting coagulation

Oral > Solid: 110 mg; 150 mg

### Indications

Venous thromboembolism

Other specified atrial fibrillation

## Dabrafenib

### Section

#### Targeted therapies

Oral > Solid: 50 mg; 75 mg

### Indications

Other specified melanoma of skin

## Dacarbazine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

### Indications

Hodgkin lymphoma

## Daclatasvir

| Section                                                                                                                                                        | Indications         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 30 mg (as dihydrochloride); 60 mg (as dihydrochloride) | Chronic hepatitis C |

## Daclatasvir + sofosbuvir

| Section                                                                                                                                     | Indications         |
|---------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 60 mg (as dihydrochloride) + 400 mg | Chronic hepatitis C |

## Dactinomycin

| Section                                                                                          | Indications                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > IV: 500 µg in vial powder for injection | Malignant trophoblastic neoplasms of placenta<br>Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Malignant neoplasms of kidney, except renal pelvis<br>Rhabdomyosarcoma primary site<br>Ewing sarcoma of bone and articular cartilage of unspecified sites |

## Dalteparin

| Section                         | Indications                                                                                                                                     |
|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines affecting coagulation | Therapeutic equivalent to enoxaparin for<br>Acute ischaemic heart disease<br>Therapeutic equivalent to enoxaparin for<br>Venous thromboembolism |

## Dapagliflozin

| Section                   | Indications                                                             |
|---------------------------|-------------------------------------------------------------------------|
| Oral hypoglycaemic agents | Therapeutic equivalent to empagliflozin for<br>Type 2 diabetes mellitus |

## Dapsone

| Section                                                                          | Indications |
|----------------------------------------------------------------------------------|-------------|
| Antileprosy medicines<br>Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet | Leprosy     |

## Daptomycin

| Section                                                                                                                                     | Indications                        |
|---------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Reserve group antibiotics<br>Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection | Other specified bacterial diseases |

## Daratumumab

| Section                                                                                     | Indications         |
|---------------------------------------------------------------------------------------------|---------------------|
| Immunomodulators<br>Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL | Plasma cell myeloma |

## Darbepoetin alfa

| Section               | Indications                                                                                       |
|-----------------------|---------------------------------------------------------------------------------------------------|
| Antianaemia medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br>Anaemia due to chronic disease |
| Supportive medicines  | Therapeutic equivalent to erythropoiesis-stimulating agents for<br>Drug-induced aplastic anaemia  |

## Darunavir

| Section                                                                              | Indications                                                                                                         |
|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Protease inhibitors<br>Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Dasabuvir

| Section                                                                                                          | Indications         |
|------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 250 mg tablet | Chronic hepatitis C |

## Dasatinib

### Section

#### Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

### Indications

Chronic myeloid leukaemia, not elsewhere classified

## Daunorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### Indications

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

Myeloid leukaemia

## Deferasirox

### Section

#### Other medicines for haemoglobinopathies

Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

### Indications

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

Therapeutic equivalent to [deferoxamine](#) for

Thalassaemias

## Deferiprone

### Section

#### Other medicines for haemoglobinopathies

### Indications

Therapeutic equivalent to [deferasirox](#) for

Other specified sickle cell disorders or other haemoglobinopathies

Therapeutic equivalent to [deferasirox](#) for

Thalassaemias

## Deferoxamine

### Section

#### Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

#### Other medicines for haemoglobinopathies

Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

### Indications

Harmful effects of drugs, medicaments or biological substances, not elsewhere classified

Other specified sickle cell disorders or other haemoglobinopathies

Thalassaemias

## Delafloxacin

| Section                                                                                                                                          | Indications                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| <a href="#">Watch group antibiotics</a><br>Parenteral > General injections > IV: 300 mg lyophilized powder for injection<br>Oral > Solid: 450 mg | Methicillin resistant <i>Staphylococcus aureus</i> |

## Delamanid

| Section                                                                                                                | Indications                                            |
|------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <a href="#">Antituberculosis medicines</a><br>Oral > Solid > dispersible tablet: 25 mg<br>Oral > Solid > tablet: 50 mg | Multi-drug resistant <i>Mycobacterium tuberculosis</i> |

## Dengue vaccine

| Section                                                                                                                         | Indications                                                 |
|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| <a href="#">Immunologicals &gt; Vaccines</a><br>All vaccines should comply with the WHO requirements for biological substances. | Need for immunization against certain single viral diseases |

## Desmopressin

| Section                                                                                                                                                                                 | Indications                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| <a href="#">Medicines affecting coagulation</a><br>Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)<br>Local > Nasal > Spray: 150 µg per actuation (acetate) | Haemophilia A<br>Von Willebrand disease |

## Dexamethasone

| Section                                                                                                                                                                                                                                                                                                                                                                                  | Indications                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Other medicines administered to the mother</a><br>Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))                                                                                                                                                                                                                           | Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy                                                                                                                            |
| <a href="#">Hormones and antihormones</a><br>Oral > Liquid: 2 mg per 5 mL<br>Oral > Solid: 2 mg; 4 mg<br>Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)<br>Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base) | Anaplastic large cell lymphoma, ALK-negative<br>Plasma cell myeloma<br>Burkitt lymphoma including Burkitt leukaemia<br>Lymphoid leukaemia, not elsewhere classified<br>Anaplastic large cell lymphoma, ALK-positive |

Oral > Solid > tablet: 4 mg (as dexamethasone base)

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

#### Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per 5 mL (as sodium phosphate); 0.5 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (dexamethasone phosphate (as sodium phosphate) equivalent to 3.3 mg dexamethasone base)

Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base); 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base)

#### Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)

#### Antiemetic medicines

Oral > Liquid: 0.5 mg per 5 mL (as sodium phosphate); 2 mg per 5 mL (as sodium phosphate)

Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)

Oral > Solid > tablet: 0.5 mg (as dexamethasone base); 0.75 mg (as dexamethasone base); 1.5 mg (as dexamethasone base); 4 mg (as dexamethasone base); 2 mg (as dexamethasone base)

Palliative care

Allergic or hypersensitivity conditions of unspecified type

Nausea or vomiting

## Dextran 40

### Section

Plasma substitutes

.

### Indications

Hypovolaemia

## Dextran 70

| Section                                                                            | Indications  |
|------------------------------------------------------------------------------------|--------------|
| Plasma substitutes<br>Parenteral > General injections > IV: 6% injectable solution | Hypovolaemia |

## Diaphragms

| Section              | Indications                                               |
|----------------------|-----------------------------------------------------------|
| Barrier methods<br>- | Contact with health services for contraceptive management |

## Diazepam

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Indications                                                                         |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Medicines for anxiety disorders<br>Oral > Solid: 5 mg (scored); 2 mg (scored)                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Anxiety                                                                             |
| Antiseizure medicines<br>Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system<br>Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube                                                                                                                                                                                                       | Therapeutic equivalent to lorazepam for<br>Status epilepticus<br>Status epilepticus |
| Medicines for other common symptoms in palliative care<br>Oral > Liquid: 2 mg per 5 mL<br>Local > Rectal > Gel: 5 mg per mL in 0.5 mL rectal delivery system; 5 mg per mL in 2 mL rectal delivery system; 5 mg per mL in 4 mL rectal delivery system<br>Local > Rectal > Solution: 2 mg per mL in 1.25 mL rectal tube; 2 mg per mL in 2.5 mL rectal tube; 4 mg per mL in 2.5 mL rectal tube<br>Parenteral > General injections > unspecified: 5 mg per mL<br>Oral > Solid > tablet: 5 mg (scored); 10 mg (scored); 2 mg (scored) | Palliative care                                                                     |

## Diazoxide

| Section                                                                           | Indications                                           |
|-----------------------------------------------------------------------------------|-------------------------------------------------------|
| Medicines for hypoglycaemia<br>Oral > Liquid: 50 mg per mL<br>Oral > Solid: 50 mg | Persistent hyperinsulinaemic hypoglycaemia of infancy |

## Didanosine

### Section

[Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution

Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Diethylcarbamazine

### Section

[Antifilarials](#)

Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)

### Indications

Lymphatic filariasis

## Digitoxin

### Section

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule

Oral > Solid: 50 µg; 100 µg

### Indications

Heart failure

## Digoxin

### Section

[Antiarrhythmic medicines](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid: 62.5 µg; 250 µg

[Medicines used in heart failure](#)

Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule; 100 µg per mL in 1 mL ampoule

Oral > Liquid: 50 µg per mL

Oral > Solid > tablet: 62.5 µg; 250 µg; 125 µg

### Indications

Cardiac arrhythmia

Heart failure

## Dihydroartemisinin + piperaquine

### Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > dispersible tablet: 20 mg + 160 mg (phosphate); 40 mg + 320 mg (phosphate)

Oral > Solid > tablet: 40 mg + 320 mg (phosphate); 20 mg + 160 mg (phosphate); 60 mg + 480 (phosphate); 80 mg + 640 mg (phosphate)

### Indications

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Dihydroergocryptine mesylate

### Section

Antiseizure medicines

Oral > Solid:

### Indications

Parkinson disease

## Diloxanide

### Section

Antiamoebic and anti giardiasis medicines

Oral > Solid: 500 mg (furoate)

### Indications

Amoebiasis

## Dimercaprol

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule; 100 mg per mL in 3 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Dinoprostone (prostaglandin E2)

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 1 mg per mL

### Indications

Other specified congenital anomaly of great arteries including arterial duct

Therapeutic equivalent to alprostadil (prostaglandin E1) for

Other specified congenital anomaly of great arteries including arterial duct

## Diphtheria antitoxin

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies

Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial

### Indications

Need for immunization against diphtheria alone

## Diphtheria vaccine

### Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against diphtheria alone

## Diphtheria-pertussis-tetanus vaccine

### Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against diphtheria-tetanus-pertussis, combined

## Diphtheria-tetanus vaccine

### Section

[Immunologicals > Vaccines](#)

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against combinations of infectious diseases

## Docetaxel

### Section

[Cytotoxic medicines](#)

Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

### Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Malignant neoplasms of prostate

Unspecified malignant neoplasms of ill-defined or unspecified sites

## Docusate sodium

### Section

[Medicines for other common symptoms in palliative care](#)

Oral > Liquid: 50 mg per 5 mL; 12.5 mg per 5 mL

Oral > Solid > capsule: 100 mg

### Indications

Palliative care

## Dolasetron

| Section                                                | Indications                                                     |
|--------------------------------------------------------|-----------------------------------------------------------------|
| Medicines for other common symptoms in palliative care | Therapeutic equivalent to ondansetron for<br>Palliative care    |
| Antiemetic medicines                                   | Therapeutic equivalent to ondansetron for<br>Nausea or vomiting |

## Dolutegravir

| Section                                                                                                  | Indications                                                                                                               |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Integrase inhibitors<br>Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored) | Human immunodeficiency virus disease<br>without mention of associated disease or<br>condition, clinical stage unspecified |

## Dolutegravir + lamivudine + tenofovir

| Section                                                                                                                                                       | Indications                                                                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) | Human immunodeficiency virus disease<br>without mention of associated disease or<br>condition, clinical stage unspecified |

## Donepezil

| Section                                                                                                                                                                                                                                         | Indications                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| Medicines for diseases of the nervous system<br>Oral > Liquid: 1 mg per mL (hydrochloride)<br>Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 5 mg (hydrochloride) (orodispersible); 10 mg (hydrochloride) (orodispersible) | Dementia due to Alzheimer disease |

## Dopamine

| Section                                                                                                            | Indications                        |
|--------------------------------------------------------------------------------------------------------------------|------------------------------------|
| Medicines used in heart failure<br>Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride) | Heart failure<br>Cardiogenic shock |

## Dostarlimab

| Section                                                                                                                    | Indications                                         |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Immunomodulators<br>Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion | Other specified malignant neoplasms of corpus uteri |

## Doxorubicin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Rhabdomyosarcoma primary site

Malignant neoplasms of breast

Hodgkin lymphoma

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of kidney, except renal pelvis

Osteosarcoma of bone and articular cartilage of unspecified sites

Anaplastic large cell lymphoma, ALK-negative

Other specified malignant neoplasms of breast

Anaplastic large cell lymphoma, ALK-positive

Ewing sarcoma of bone and articular cartilage of unspecified sites

Kaposi sarcoma of unspecified primary site

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Diffuse large B-cell lymphoma, not otherwise specified

## Doxorubicin (as pegylated liposomal)

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

### Indications

Kaposi sarcoma of unspecified primary site

## Doxycycline

### Section

#### Access group antibiotics

Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)

Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)

Parenteral > General injections > unspecified: 100 mg in vial powder for injection

Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium)

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

Oral > Solid > dosage form: 100 mg (as hyclate)

#### Antimalarial medicines > Medicines for chemoprophylaxis in travellers

Oral > Liquid: 50 mg per 5 mL (calcium); 25 mg per 5 mL (monohydrate) powder for oral liquid

Oral > Solid > dispersible tablet: 100 mg (as monohydrate)

Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate)

#### Antimalarial medicines > Medicines for curative treatment

Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)

#### Antimalarial medicines > Medicines for chemoprevention

Oral > Solid: 100 mg (hydrochloride or hyclate)

### Indications

#### First choice

Chlamydia trachomatis

Cholera

#### Second choice

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Chronic obstructive pulmonary disease with acute exacerbation

Cholera [children]

#### Other indications

Bacterial infection of unspecified site

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

Malaria due to Plasmodium falciparum

## Dulaglutide

### Section

#### Hypoglycaemic agents

### Indications

Therapeutic equivalent to semaglutide for

Obesity

Therapeutic equivalent to semaglutide for

Type 2 diabetes mellitus

## Durvalumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Hepatocellular carcinoma of liver

Malignant neoplasms of biliary tract, distal bile duct

Malignant neoplasm of intrahepatic bile ducts

Malignant neoplasms of gallbladder

Malignant neoplasms of proximal biliary tract, cystic duct

## Edoxaban

### Section

#### Medicines affecting coagulation

### Indications

Therapeutic equivalent to [dabigatran](#) for

Venous thromboembolism

Therapeutic equivalent to [dabigatran](#) for

Other specified atrial fibrillation

## Efavirenz

### Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors  
Oral > Solid: 600 mg tablet

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + emtricitabine + tenofovir

### Section

Fixed-dose combinations of antiretrovirals  
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Efavirenz + lamivudine + tenofovir

### Section

#### Fixed-dose combinations of antiretrovirals

Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine + tenofovir for

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Eflornithine

### Section

#### Medicines for the treatment of 2nd stage African trypanosomiasis

Parenteral > General injections > IV: 200 mg per mL in 50 mL bottle (hydrochloride)

### Indications

Gambiense trypanosomiasis

## Elbasvir + grazoprevir

### Section

#### Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 100 mg

### Indications

Chronic hepatitis C

## Eletriptan

### Section

#### Medicines for acute migraine attacks

Oral > Solid > tablet: 40 mg

### Indications

Therapeutic equivalent to sumatriptan for

Migraine

## Elexacaftor + tezacaftor + ivacaftor

### Section

#### Medicines for cystic fibrosis

Oral > Solid > tablet: 50 mg + 25 mg + 37.5 mg; 100 mg + 50 mg + 75 mg

Oral > Solid > granules: 80 mg + 40 mg + 60 mg in sachet; 100 mg + 50 mg + 75 mg in sachet

### Indications

Cystic fibrosis

## Emicizumab

| Section                                                                                                                                                                                                                         | Indications   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Medicines affecting coagulation<br>Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial | Haemophilia A |

## Empagliflozin

| Section                                                 | Indications              |
|---------------------------------------------------------|--------------------------|
| Oral hypoglycaemic agents<br>Oral > Solid: 10 mg; 25 mg | Type 2 diabetes mellitus |

## Emtricitabine

| Section                                                                                                                         | Indications                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Liquid: 10 mg per mL<br>Oral > Solid: 200 mg | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Emtricitabine + rilpivirine + tenofovir alafenamide

| Section                                                                            | Indications                                                                                                         |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 200 mg + 25 mg + 25 mg | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

| Section                                                                                                                                                       | Indications                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Emtricitabine + tenofovir

| Section                                                                                                                                               | Indications                                                                                                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil) | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified<br>Contact with or exposure to human immunodeficiency virus |

## Emtricitabine + tenofovir alafenamide

### Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Enalapril

### Section

Antihypertensive medicines

Oral > Liquid: 1 mg per mL (as hydrogen maleate)

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

Medicines used in heart failure

Oral > Solid > tablet: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate); 10 mg (as hydrogen maleate)

### Indications

Essential hypertension

Heart failure

## Encorafenib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to [dabrafenib](#) for

Other specified melanoma of skin

## Enoxaparin

### Section

Medicines affecting coagulation

Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

### Indications

Acute ischaemic heart disease

Venous thromboembolism

## Entecavir

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 0.05 mg per mL

Oral > Solid: 0.5 mg; 1 mg

### Indications

Chronic hepatitis B

## Enzalutamide

### Section

Hormones and antihormones

Oral > Solid: 40 mg

### Indications

Therapeutic equivalent to abiraterone for

Malignant neoplasms of prostate

Malignant neoplasms of prostate

## Ephedrine

### Section

Local anaesthetics

Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)

### Indications

Cardiac complications of anaesthesia during labour or delivery

## Epinephrine

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)

Ophthalmological preparations > Mydriatics

Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)

Antiallergics and medicines used in anaphylaxis

Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)

### Indications

Cardiac arrest

Primary open-angle glaucoma

Asthma

Chronic obstructive pulmonary disease

Anaphylaxis

## Epoetin alfa

### Section

Antianaemia medicines

### Indications

Therapeutic equivalent to erythropoiesis-stimulating agents for

Anaemia due to chronic disease

Supportive medicines

Therapeutic equivalent to erythropoiesis-stimulating agents for

Drug-induced aplastic anaemia

## Epoetin beta

| Section               | Indications                                                                                                       |
|-----------------------|-------------------------------------------------------------------------------------------------------------------|
| Antianaemia medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br><a href="#">Anaemia due to chronic disease</a> |
| Supportive medicines  | Therapeutic equivalent to erythropoiesis-stimulating agents for<br><a href="#">Drug-induced aplastic anaemia</a>  |

## Epoetin theta

| Section               | Indications                                                                                                       |
|-----------------------|-------------------------------------------------------------------------------------------------------------------|
| Antianaemia medicines | Therapeutic equivalent to erythropoiesis-stimulating agents for<br><a href="#">Anaemia due to chronic disease</a> |

## Eptinezumab

| Section                            | Indications                                                                                    |
|------------------------------------|------------------------------------------------------------------------------------------------|
| Medicines for migraine prophylaxis | Therapeutic equivalent to <a href="#">fremanezumab</a> for<br><a href="#">Chronic migraine</a> |

## Equine rabies immunoglobulin

| Section                                                                                                                                                                                                               | Indications            |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| Immunologicals > Sera, immunoglobulins and monoclonal antibodies<br>Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial;<br>200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial | <a href="#">Rabies</a> |

## Eravacycline

| Section                                                                                                   | Indications                                           |
|-----------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Reserve group antibiotics<br>Parenteral > General injections > IV: 50 mg lyophilized powder for injection | <a href="#">Carbapenem resistant Enterobacterales</a> |

## Erenumab

### Section

Medicines for migraine prophylaxis

### Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

## Ergocalciferol

### Section

Vitamins and minerals

Oral > Liquid: 250 µg per mL (10 000 IU per mL)

Oral > Solid: 1.25 mg (50 000 IU)

### Indications

Therapeutic equivalent to [colecalfiferol](#) for

Calcium deficiency

Therapeutic equivalent to [colecalfiferol](#) for

Vitamin D deficiency

Vitamin D deficiency

Calcium deficiency

## Ergometrine

### Section

Uterotonics

Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)

### Indications

Postpartum haemorrhage

## Erlotinib

### Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

### Indications

Other specified malignant neoplasms of bronchus or lung

## Erythromycin

### Section

Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)

Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)

Oral > Solid: 250 mg (as stearate or ethylsuccinate)

### Indications

#### Second choice

Therapeutic equivalent to [clarithromycin](#) for

Acute pharyngitis

#### Other indications

Bacterial infection of unspecified site

Chlamydial conjunctivitis

Gonococcal infection of eye

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Ointment: 0.5%

## Erythropoiesis-stimulating agents

### Section

#### Antianaemia medicines

Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

#### Supportive medicines

Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

### Indications

Anaemia due to chronic disease

Drug-induced aplastic anaemia

## Estradiol

### Section

#### Estrogens

Oral > Solid > tablet: 0.5 mg; 1 mg; 2 mg

### Indications

Gonadotropin deficiency

Hypopituitarism

Turner syndrome

## Estradiol cypionate + medroxyprogesterone acetate

### Section

#### Injectable hormonal contraceptives

Parenteral > General injections > IM: 5 mg + 25 mg

### Indications

Contact with health services for reasons associated with reproduction

## Etanercept

### Section

Immunomodulators for non-malignant disease

Medicines for juvenile joint diseases

Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

## Ethambutol

### Section

Antituberculosis medicines

Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL

Oral > Solid > dispersible tablet: 100 mg

Oral > Solid > tablet: 100 mg (hydrochloride); 400 mg (hydrochloride)

### Indications

Other specified tuberculosis

Tuberculosis

## Ethambutol + isoniazid

### Section

Antituberculosis medicines

Oral > Solid: 400 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethambutol + isoniazid + pyrazinamide + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethambutol + isoniazid + rifampicin

### Section

Antituberculosis medicines

Oral > Solid: 275 mg + 75 mg + 150 mg tablet

### Indications

Tuberculosis

## Ethanol

### Section

#### Antiseptics

Local > Topical > Solution: 70% (denatured)

### Indications

Denatured alcohol

## Ether

### Section

#### General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > solution:

### Indications

Anaesthetics and therapeutic gases

## Ethinylestradiol + etonogestrel

### Section

#### Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

### Indications

Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

### Section

#### Oral hormonal contraceptives

Oral > Solid: 50 µg + 250 µg [4]

Oral > Solid: 30 µg + 150 µg

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

### Section

#### Oral hormonal contraceptives

Oral > Solid: 35 µg + 1 mg

### Indications

Contact with health services for contraceptive management

## Ethionamide

### Section

#### Antituberculosis medicines

Oral > Solid > dispersible tablet: 125 mg

Oral > Solid > tablet: 250 mg

### Indications

Tuberculous meningitis

Multi-drug resistant Mycobacterium tuberculosis

## Ethosuximide

| Section                                                                                | Indications               |
|----------------------------------------------------------------------------------------|---------------------------|
| <b>Antiseizure medicines</b><br>Oral > Liquid: 250 mg per 5 mL<br>Oral > Solid: 250 mg | Absence seizures, typical |

## Etonogestrel-releasing implant

| Section                                                                    | Indications                                                        |
|----------------------------------------------------------------------------|--------------------------------------------------------------------|
| <b>Implantable contraceptives</b><br>Implant > Subdermal: 68 mg single rod | Contact with health services for insertion of contraceptive device |

## Etoposide

| Section                                                                                                                                                                                                                                                                                                   | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule<br>Oral > Solid: 100 mg capsule<br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)<br>Oral > Solid: 100 mg capsule; 50 mg capsule | Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Ewing sarcoma of bone and articular cartilage of unspecified sites<br>Other specified malignant neoplasms of the ovary<br>Other specified malignant neoplasms of bronchus or lung<br>Germ cell tumour of testis<br>Malignant trophoblastic neoplasms of placenta<br>Malignant neoplasms of kidney, except renal pelvis<br>Osteosarcoma of bone and articular cartilage of unspecified sites<br>Hodgkin lymphoma<br>Retinoblastoma<br>Anaplastic large cell lymphoma, ALK-positive<br>Anaplastic large cell lymphoma, ALK-negative<br>Lymphoid leukaemia, not elsewhere classified<br>Myeloid leukaemia<br>Burkitt lymphoma including Burkitt leukaemia |

## Everolimus

| Section                                                                                                                                | Indications                      |
|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|
| <b>Targeted therapies</b><br>Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg<br>Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg | Other specified gliomas of brain |

## Exenatide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to **semaglutide** for

Obesity

## Fentanyl

### Section

Opioid analgesics

Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour

Oral > Solid: 100 to 800 µg sub-lingual tablet (as citrate); 200 to 1600 µg lozenge (as citrate)

Oral > Other: 200 to 1200 µg buccal film (as citrate)

### Indications

Chronic cancer pain

Other specified chronic cancer related pain

## Ferrous salt

### Section

Antianaemia medicines

Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron

Oral > Solid > tablet: 60 to 65 mg elemental iron

### Indications

Iron deficiency anaemia

## Ferrous salt + folic acid

### Section

Antianaemia medicines

Oral > Solid: 60 mg iron + 2.8 mg

Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

### Indications

Iron deficiency anaemia

Clefts of lip, alveolus or palate

Iron deficiency anaemia

Anencephaly or similar anomalies

Spina bifida

## Fexinidazole

### Section

Medicines for the treatment of 1st stage African trypanosomiasis

Oral > Solid > tablet: 600 mg

Oral > Solid: 600 mg

Medicines for the treatment of 2nd stage African trypanosomiasis

Oral > Solid > tablet: 600 mg

Oral > Solid: 600 mg

### Indications

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

Rhodesiense trypanosomiasis

Gambiense trypanosomiasis

## Fexofenadine

### Section

Antiallergics and medicines used in anaphylaxis

### Indications

Therapeutic equivalent to loratadine for

Allergic or hypersensitivity conditions of unspecified type

## Fifth generation cephalosporins

### Section

Reserve group antibiotics

### Indications

Other specified bacterial diseases

## Filgrastim

### Section

Immunomodulators

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

### Indications

Acquired neutropaenia

## Fingolimod

### Section

Immunomodulators for non-malignant disease

Oral > Solid: 0.25 mg; 0.5 mg

### Indications

Relapsing-remitting multiple sclerosis

## Flomoxef

### Section

Watch group antibiotics

Parenteral > General injections > IV: 0.5 g in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified other antibiotic resistant Enterobacterales

## Fluconazole

### Section

Antifungal medicines

Parenteral > General injections > IV: 2 mg per mL in vial

Oral > Liquid: 50 mg per 5 mL; 50 mg per 5 mL powder for oral liquid

Oral > Solid > capsule: 50 mg

### Indications

Cryptococcosis

Candidosis

## Flucytosine

### Section

#### Antifungal medicines

Parenteral > General injections > IV: 2.5 g per 250 mL infusion

Oral > Solid: 250 mg capsule

### Indications

Cryptococcosis

## Fludarabine

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection

Oral > Solid: 10 mg tablet (fludarabine phosphate)

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Fludrocortisone

### Section

#### Adrenal hormones and synthetic substitutes

Oral > Liquid: 100 µg per mL

Oral > Solid > tablet: 100 µg (acetate)

### Indications

Adrenocortical insufficiency

## Flunisolide

### Section

#### Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [budesonide](#) for

Asthma

## Fluorescein

### Section

#### Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)

### Indications

Fluorescein

## Fluoride

### Section

#### Dental medicines and preparations

Local > Dental > Gel: 2500 to 12500 ppm fluoride (any type)

Local > Dental > Toothpaste, cream or gel: 1000 to 1500 ppm fluoride (any type)

Local > Dental > Mouthrinse: 230 to 900 ppm fluoride (any type)

Local > Dental > Varnish: 22500 ppm fluoride (any type)

### Indications

Dental caries

## Fluorouracil

| Section                                                                                                                                                 | Indications                                                                                                                                                                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dermatological medicines > Medicines affecting skin differentiation and proliferation<br>Local > Topical > Ointment: 5%                                 | Plantar warts                                                                                                                                                                                                                                                   |
| Cytotoxic medicines<br>Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule<br>Parenteral > General injections > IV: 50 mg per mL in vial | Unspecified malignant neoplasms of ill-defined or unspecified sites<br>Malignant neoplasms of nasopharynx<br>Malignant neoplasm metastasis in large intestine<br>Malignant neoplasms of breast<br>Malignant neoplasms of rectum<br>Malignant neoplasms of colon |

## Fluoxetine

| Section                                                                                          | Indications                                                               |
|--------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Medicines for depressive disorders<br>Oral > Solid: 20 mg (as hydrochloride)                     | Depressive disorders                                                      |
| Medicines for other common symptoms in palliative care<br>Oral > Solid: 20 mg (as hydrochloride) | Palliative care                                                           |
| Medicines for anxiety disorders<br>Oral > Solid: 20 mg (as hydrochloride)                        | Social anxiety disorder<br>Generalised anxiety disorder<br>Panic disorder |
| Medicines for obsessive compulsive disorders<br>Oral > Solid: 20 mg (as hydrochloride)           | Obsessive-compulsive disorder                                             |

## Fluphenazine

| Section                                                                                                                                             | Indications                                        |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Medicines for psychotic disorders<br>Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate) | Schizophrenia or other primary psychotic disorders |

## Flutamide

| Section                   | Indications                                                                   |
|---------------------------|-------------------------------------------------------------------------------|
| Hormones and antihormones | Therapeutic equivalent to bicalutamide for<br>Malignant neoplasms of prostate |

## Fluticasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide** for

Asthma

## Fluticasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

## Fluticasone furoate + vilanterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

## Fluvastatin

### Section

Lipid-lowering agents

### Indications

Therapeutic equivalent to **simvastatin** for

Mixed hyperlipidaemia

Therapeutic equivalent to **simvastatin** for

Coronary atherosclerosis

## Folic acid

### Section

Antianaemia medicines

Oral > Solid: 400 µg

Oral > Liquid: 1 mg per mL

Oral > Solid: 1 mg tablet; 5 mg tablet

### Indications

Anencephaly or similar anomalies

Spina bifida

Cephalocele

Folate deficiency anaemia

## Fomepizole

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule or vial (sulfate); 1 g per mL in 1.5 mL ampoule or vial (base)

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Fosfomycin (injection)

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection

### Indications

Other specified bacterial diseases

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Fourth generation cephalosporins

### Section

Watch group antibiotics

.

### Indications

Other specified bacterial diseases

## Fremanezumab

### Section

Medicines for migraine prophylaxis

Parenteral > General injections > SC: 225 mg per 1.5 mL in pre-filled syringe

### Indications

Chronic migraine

## Fresh-frozen plasma

### Section

Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Fulvestrant

### Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

### Indications

Malignant neoplasms of breast

## Furosemide

### Section

#### Medicines used in heart failure

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

#### Diuretics

Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule

Oral > Liquid: 20 mg per 5 mL; 50 mg per 5 mL

Oral > Solid > tablet: 40 mg; 20 mg

### Indications

Heart failure

Anuria or oliguria

Oedema

## Gabapentin

### Section

#### Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg

### Indications

Neuropathic pain

## Galcanezumab

### Section

#### Medicines for migraine prophylaxis

### Indications

Therapeutic equivalent to [fremanezumab](#) for

Chronic migraine

## Gallamine

### Section

#### Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)

### Indications

Muscle relaxants

## Gatifloxacin

### Section

#### Antituberculosis medicines

Oral > Solid: 200 mg; 400 mg

### Indications

Multi-drug resistant *Mycobacterium tuberculosis*

## Gefitinib

### Section

Targeted therapies

### Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

## Gemcitabine

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

### Indications

Other specified carcinomas of ovary

Other specified malignant neoplasms of bronchus or lung

## Gentamicin

### Section

Access group antibiotics

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

### Indications

#### First choice

Neonatal meningitis

co-prescribed with amoxicillin

Sepsis without septic shock

co-prescribed with amoxicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with ampicillin

Sepsis without septic shock

co-prescribed with ampicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with ampicillin

Peritoneal abscess (severe)

co-prescribed with ampicillin

Peritonitis (mild-moderate)

co-prescribed with ampicillin

Peritonitis (severe)

co-prescribed with ampicillin

Peritoneal abscess (mild-moderate)

co-prescribed with benzylpenicillin

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

co-prescribed with benzylpenicillin

Acute malnutrition in infants, children or adolescents (complicated) [children]

co-prescribed with [benzylpenicillin](#)

[Sepsis without septic shock](#)

#### Second choice

[Other specified prophylactic measures](#)

[Gonococcal infection](#)

#### Other indications

[Bacterial infection of unspecified site](#)

[Other specified conjunctivitis](#)

[Infectious blepharitis](#)

#### First choice

[Neonatal meningitis](#)

#### Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.3% (gentamicin sulfate)

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)

### Glass ionomer cement

#### Section

##### Dental medicines and preparations

Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid

#### Indications

[Dental caries](#)

### Glatiramer acetate

#### Section

##### Medicines for multiple sclerosis

Parenteral > General injections > SC: 20 mg per mL in pre-filled syringe; 40 mg per mL in pre-filled syringe

Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL

#### Indications

[Multiple sclerosis](#)

[Relapsing-remitting multiple sclerosis](#)

### Glecaprevir + pibrentasvir

#### Section

##### Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 50 mg + 20 mg granules

Oral > Solid > tablet: 100 mg + 40 mg

#### Indications

[Chronic hepatitis C](#)

## Glibenclamide

### Section

Oral hypoglycaemic agents

Oral > Solid: 5 mg; 2.5 mg

### Indications

Type 2 diabetes mellitus

## Gliclazide

### Section

Oral hypoglycaemic agents

Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release

### Indications

Type 2 diabetes mellitus

## Glucagon

### Section

Medicines for hypoglycaemia

Parenteral > General injections > unspecified: 1 mg per mL as powder and diluent

### Indications

Hypoglycaemia in the context of diabetes

## Glucose

### Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 5% isotonic; 10% hypertonic

Parenteral > General injections > IV: 50% hypertonic

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Hypoglycaemia without associated diabetes

## Glucose + sodium chloride

### Section

Solutions correcting water, electrolyte and acid-base disturbances >

Parenteral

Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na<sup>+</sup> 30 mmol/L and Cl<sup>-</sup> 30 mmol/L; 5% + 0.9% (equivalent to Na<sup>+</sup> 150 mmol/L and Cl<sup>-</sup> 150 mmol/L); 5% + 0.45% (equivalent to Na<sup>+</sup> 75 mmol/L and Cl<sup>-</sup> 75 mmol/L)

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

## Glutaral

### Section

Disinfectants

Local > Topical > Solution: 2%

### Indications

Glutaral nonmedicinal

## Glycerol

### Section

Dermatological medicines > Moisturizers  
Local > Topical > Cream: 15 to 20%

### Indications

Atopic eczema

## Glyceryl trinitrate

### Section

Antianginal medicines  
Oral > Solid: 500 µg sublingual tablet

### Indications

Angina pectoris

## Glycopyrronium

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to [tiotropium bromide](#) for

Chronic obstructive pulmonary disease

## Golimumab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

## Goserelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of prostate

## Granisetron

| Section                                                | Indications                                                     |
|--------------------------------------------------------|-----------------------------------------------------------------|
| Medicines for other common symptoms in palliative care | Therapeutic equivalent to ondansetron for<br>Palliative care    |
| Antiemetic medicines                                   | Therapeutic equivalent to ondansetron for<br>Nausea or vomiting |

## Griseofulvin

| Section                                                                                | Indications     |
|----------------------------------------------------------------------------------------|-----------------|
| Antifungal medicines<br>Oral > Liquid: 125 mg per 5 mL<br>Oral > Solid: 125 mg; 250 mg | Dermatophytosis |

## Haemophilus influenzae type b vaccine

| Section                                                                                                      | Indications                                             |
|--------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Immunologicals > Vaccines<br>All vaccines should comply with the WHO requirements for biological substances. | Need for immunization against single bacterial diseases |

## Haloperidol

| Section                                                                                                                                                                                                | Indications                                        |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
| Medicines for other common symptoms in palliative care<br>Oral > Liquid: 2 mg per mL<br>Oral > Solid: 0.5 mg; 2 mg; 5 mg<br>Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule | Palliative care                                    |
| Medicines for psychotic disorders<br>Parenteral > General injections > IM: 5 mg per mL in ampoule<br>Oral > Solid: 2 mg; 5 mg                                                                          | Schizophrenia or other primary psychotic disorders |

## Haloperidol decanoate

| Section                           | Indications                                                                                      |
|-----------------------------------|--------------------------------------------------------------------------------------------------|
| Medicines for psychotic disorders | Therapeutic equivalent to fluphenazine for<br>Schizophrenia or other primary psychotic disorders |

## Halothane

### Section

General anaesthetics and oxygen > Inhalational medicines  
Respiratory > Inhalation > liquid:

### Indications

Anaesthetics and therapeutic gases

## Heparin sodium

### Section

Medicines affecting coagulation  
Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

### Indications

Acute ischaemic heart disease

Unstable angina

Venous thromboembolism

## Hepatitis A vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Hepatitis B vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Hepatitis E vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against viral hepatitis

## Homatropine

### Section

Ophthalmological preparations > Mydriatics  
Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)

### Indications

Anterior uveitis

Therapeutic equivalent to atropine for

Anterior uveitis

## Human papilloma virus (HPV) vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Hydralazine

### Section

#### Antihypertensive medicines

Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)

Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)

Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)

### Indications

Essential hypertension

Gestational hypertension

## Hydrochlorothiazide

### Section

#### Antihypertensive medicines

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg; 12.5 mg

#### Medicines used in heart failure

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 25 mg

#### Diuretics

Oral > Solid > dosage form: 25 mg; 12.5 mg

### Indications

Essential hypertension

Heart failure

Oedema

## Hydrocortisone

| Section                                                                                                                                                                                         | Indications                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Hormones and antihormones</b><br>Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)                                                                         | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Lymphoid leukaemia, not elsewhere classified</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> |
| <b>Ophthalmological preparations &gt; Anti-inflammatory agents</b><br>Local > Ophthalmological > Ointment: 1% (acetate)                                                                         | <div>Scleritis</div> <div>Anterior uveitis</div>                                                                                                                                               |
| <b>Antiallergics and medicines used in anaphylaxis</b><br>Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)                              | <div>Anaphylaxis</div>                                                                                                                                                                         |
| <b>Anti-inflammatory medicines</b><br>Local > Rectal > Suppository: 25 mg (acetate)<br>Local > Rectal > Retention enema: 100 mg per 60 mL                                                       | <div>Crohn disease site</div> <div>Ulcerative colitis</div>                                                                                                                                    |
| <b>Dermatological medicines &gt; Anti-inflammatory and antipruritic medicines</b><br>Local > Topical > Cream: 1% (acetate)<br>Local > Topical > Ointment: 1% (acetate)                          | <div>Dermatitis or eczema</div> <div>Lichen planus</div> <div>Pruritus due to skin disorder</div> <div>Psoriasis of unspecified type</div>                                                     |
| <b>Adrenal hormones and synthetic substitutes</b><br>Oral > Solid > tablet: 5 mg; 10 mg; 20 mg<br>Oral > Solid > granules: 0.5 mg in capsule; 1 mg in capsule; 2 mg in capsule; 5 mg in capsule | <div>Adrenocortical insufficiency</div>                                                                                                                                                        |

## Hydromorphone

| Section                  | Indications                                                       |
|--------------------------|-------------------------------------------------------------------|
| <b>Opioid analgesics</b> | <div>Therapeutic equivalent to morphine for</div> <div>Pain</div> |

## Hydroxocobalamin

| Section                                                                                                                                                                                                  | Indications                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|
| <b>Antianaemia medicines</b><br>Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate) | <div>Megaloblastic anaemia due to vitamin B12 deficiency</div> |

## Hydroxycarbamide (hydroxyurea)

| Section                                                                                                                                                            | Indications                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g<br>Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg | <b>Squamous cell carcinoma of oropharynx</b><br><b>Chronic myeloid leukaemia, not elsewhere classified</b> |
| <b>Other medicines for haemoglobinopathies</b><br>Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg                                                          | <b>Other specified sickle cell disorders or other haemoglobinopathies</b>                                  |

## Hydroxychloroquine

| Section                                                                                     | Indications                                                                                     |
|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| <b>Antimalarial medicines &gt; For chemoprevention</b>                                      | Therapeutic equivalent to <b>chloroquine</b> for<br><b>Malaria due to Plasmodium falciparum</b> |
| <b>Disease-modifying anti-rheumatic drugs (DMARDs)</b><br>Oral > Solid: 200 mg (as sulfate) | <b>Systemic lupus erythematosus</b><br><b>Cutaneous lupus erythematosus of unspecified type</b> |

## Hyoscine butylbromide

| Section                                                                                                                                | Indications            |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <b>Medicines for other common symptoms in palliative care</b><br>Parenteral > General injections > unspecified: 20 mg per mL injection | <b>Palliative care</b> |

## Hyoscine hydrobromide

| Section                                                                                                                                                                                                                                      | Indications            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <b>Medicines for other common symptoms in palliative care</b><br>Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch<br>Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection | <b>Palliative care</b> |

## Hypochlorous acid

| Section                                                                                               | Indications                                   |
|-------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| <b>Disinfectants</b><br>Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million | <b>Disinfectant, not elsewhere classified</b> |
| <b>Antiseptics</b><br>Solution (aqueous): containing hypochlorous acid $\geq$ 150 parts per million   | <b>Hypochlorite</b>                           |

## Hypromellose

### Section

Ophthalmological preparations

Local > Ophthalmological > Solution (eye drops): 0.3%

### Indications

Keratoconjunctivitis sicca

## Ibrutinib

### Section

Targeted therapies

Oral > Solid: 140 mg

### Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Ibuprofen

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)

Oral > Liquid: 200 mg per 5 mL; 100 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg; 600 mg

Medicines for acute migraine attacks

Oral > Liquid: 100 mg per 5 mL; 200 mg per 5 mL

Oral > Solid > tablet: 200 mg; 400 mg

### Indications

Patent arterial duct

Pain

Migraine

## Idoxuridine

### Section

Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 0.1%

Local > Ophthalmological > Ointment: 0.2%

### Indications

Herpes simplex keratitis

## Ifosfamide

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection

Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

### Indications

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Osteosarcoma of bone and articular cartilage of unspecified sites

Rhabdomyosarcoma primary site

Unspecified malignant neoplasms of ill-defined or unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Burkitt lymphoma including Burkitt leukaemia

## Imatinib

### Section

#### Targeted therapies

Oral > Solid: 100 mg; 400 mg

### Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

## Imipenem + cilastatin

| Section                                                                                                                                                                                                                          | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Watch group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection</p> | <p><b>Second choice</b></p> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <p>Neutropenia (high-risk)</p> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <p>Peritoneal abscess (severe)</p> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <p>Peritonitis (severe)</p> <p><b>Other indications</b></p> <p>Pseudomonas aeruginosa resistant to other antibiotic</p> <p>Antibiotic resistant Acinetobacter baumannii</p> <p>Therapeutic equivalent to <a href="#">meropenem</a> for</p> <p>Multi-drug resistant Mycobacterium tuberculosis</p> |
| Antituberculosis medicines                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

## Imipenem + cilastatin + relebactam

| Section                                                                                                                                                                                                                                                                          | Indications                                                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>Reserve group antibiotics</p> <p>Parenteral &gt; General injections &gt; IV: 500 mg + 500 mg + 250 mg powder for injection</p> <p>Parenteral &gt; General injections &gt; IV: 500 mg (as monohydrate) + 500 mg (as sodium) + 250 mg (as monohydrate) powder for injection</p> | <p>Other specified other antibiotic resistant Enterobacterales</p> <p>Carbapenem resistant Enterobacterales</p> <p>Carbapenem-resistant Pseudomonas aeruginosa</p> |

## Indapamide

| Section                         | Indications                                                                                            |
|---------------------------------|--------------------------------------------------------------------------------------------------------|
| Antihypertensive medicines      | <p>Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for</p> <p>Essential hypertension</p> |
| Medicines used in heart failure | <p>Therapeutic equivalent to <a href="#">hydrochlorothiazide</a> for</p> <p>Heart failure</p>          |

## Indinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Indometacin

### Section

Medicines administered to the neonate [c]

### Indications

Therapeutic equivalent to [ibuprofen](#) for

Patent arterial duct

## Infliximab

### Section

Immunomodulators for non-malignant disease

### Indications

Therapeutic equivalent to [adalimumab](#) for

Axial spondyloarthritis

Therapeutic equivalent to [adalimumab](#) for

Crohn disease site

Therapeutic equivalent to [adalimumab](#) for

Rheumatoid arthritis

Medicines for juvenile joint diseases

Therapeutic equivalent to [adalimumab](#) for

Juvenile idiopathic arthritis

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Therapeutic equivalent to [adalimumab](#) for

Psoriasis of unspecified type

## Influenza vaccine (seasonal)

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against influenza

## Insulin (analogue, long-acting)

| Section                                                                                                                                                                                | Indications                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Insulins</b><br>Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution; 100 IU per mL in 10 mL vial solution | <input type="text" value="Type 2 diabetes mellitus"/><br><input type="text" value="Type 1 diabetes mellitus"/> |

## Insulin (analogue, rapid-acting)

| Section                                                                                                                                                           | Indications                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Insulins</b><br>Parenteral > General injections > SC: 100 IU per 1 mL in 10 mL vial; 100 IU per 1 mL in 3 mL cartridge; 100 IU per 1 mL in 3 mL pre-filled pen | <input type="text" value="Type 1 diabetes mellitus"/><br><input type="text" value="Type 2 diabetes mellitus"/> |

## Insulin (human, intermediate-acting)

| Section                                                                                                                                                                                                                                                                                                                                                                                                                 | Indications                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Insulins</b><br>Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL cartridge as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 3 mL pre-filled pen as compound insulin zinc suspension or isophane insulin | <input type="text" value="Type 2 diabetes mellitus"/><br><input type="text" value="Type 1 diabetes mellitus"/> |

## Insulin (human, short-acting)

| Section                                                                                                                                                                                                                     | Indications                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Insulins</b><br>Parenteral > General injections > SC: 40 IU per mL in 10 mL vial solution; 100 IU per mL in 10 mL vial solution; 100 IU per mL in 3 mL cartridge solution; 100 IU per mL in 3 mL pre-filled pen solution | <input type="text" value="Type 2 diabetes mellitus"/><br><input type="text" value="Type 1 diabetes mellitus"/> |

## Insulin analogues

| Section                          | Indications                                                                                                    |
|----------------------------------|----------------------------------------------------------------------------------------------------------------|
| <b>Insulins</b><br>Not specified | <input type="text" value="Type 1 diabetes mellitus"/><br><input type="text" value="Type 2 diabetes mellitus"/> |

## Insulin aspart

### Section

#### Insulins

Parenteral > General injections > SC: 100 IU per mL in 110 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, rapid-acting) for

Type 2 diabetes mellitus

## Insulin degludec

### Section

#### Insulins

Parenteral > General injections > SC: 100 units per mL

### Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Insulin detemir

### Section

#### Insulins

### Indications

Therapeutic equivalent to insulin glargine for

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Insulin glargine

### Section

#### Insulins

Parenteral > General injections > SC: 100 units per mL

### Indications

Type 1 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 2 diabetes mellitus

Therapeutic equivalent to insulin (analogue, long-acting) for

Type 1 diabetes mellitus

## Insulin glulisine

### Section

#### Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

[Type 1 diabetes mellitus](#)

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

[Type 2 diabetes mellitus](#)

## Insulin lispro

### Section

#### Insulins

Parenteral > General injections > SC: 100 IU per mL in 10 mL vial; 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled pen

### Indications

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

[Type 1 diabetes mellitus](#)

Therapeutic equivalent to [insulin \(analogue, rapid-acting\)](#) for

[Type 2 diabetes mellitus](#)

## Intraperitoneal dialysis solution

### Section

#### Peritoneal dialysis solution

Solution: of appropriate composition in accordance with local clinical guidelines.

### Indications

[Care involving peritoneal dialysis](#)

## Iodine

### Section

#### Antiseptics

#### Vitamins and minerals

Parenteral > General injections > IM: 480 mg per mL in 10 mL ampoule or vial iodized oil (oral or injectable)

### Indications

Therapeutic equivalent to [povidone iodine](#) for

[Povidone iodine](#)

[Iodine deficiency](#)

## Iodine + potassium iodide (Lugol's solution)

### Section

#### Thyroid hormones and antithyroid medicines

Oral > Liquid: 5% w/v + 10% w/v (aqueous)

### Indications

[Thyrotoxicosis](#)

## Iohexol

### Section

Diagnostic agents > Radiocontrast media

Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule

### Indications

X-ray contrast media, iodinated

## Ipecacuanha

### Section

Antidotes and other substances used in poisonings > Non-specific  
Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine

### Indications

Unspecified injury, poisoning or certain other consequences of external causes

## Ipilimumab

### Section

Immunomodulators

Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Melanoma of skin

## Ipratropium bromide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease  
Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler

### Indications

Chronic obstructive pulmonary disease

Asthma

## Irinotecan

### Section

Cytotoxic medicines

Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

## Isoflurane

### Section

General anaesthetics and oxygen > Inhalational medicines  
Respiratory > Inhalation > liquid:

### Indications

Anaesthetics and therapeutic gases

## Isoniazid

### Section

Antituberculosis medicines  
Parenteral > General injections > IV: 100 mg per mL  
Oral > Solid > dispersible tablet: 100 mg (scored)  
Oral > Solid > tablet: 100 mg; 300 mg

### Indications

Other specified tuberculosis

Tuberculosis

## Isoniazid + pyrazinamide + rifampicin

### Section

Antituberculosis medicines  
Oral > Solid > dispersible tablet: 50 mg + 150 mg + 75 mg

### Indications

Tuberculosis

## Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

### Section

Medicines for prevention of HIV-related opportunistic infections  
Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

### Indications

Other specified prophylactic measures

## Isoniazid + rifampicin

### Section

Antituberculosis medicines  
Oral > Solid > dispersible tablet: 50 mg + 75 mg  
Oral > Solid > tablet: 75 mg + 150 mg; 150 mg + 300 mg

### Indications

Tuberculosis

## Isoniazid + rifapentine

### Section

Antituberculosis medicines  
Oral > Solid: 300 mg + 300 mg tablet (scored)

### Indications

Latent tuberculosis

## Isoprenaline

### Section

#### Antiarrhythmic medicines

Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)

Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)

### Indications

Bradycardia

Cardiogenic shock

## Isosorbide dinitrate

### Section

#### Antianginal medicines

Oral > Solid: 5 mg sublingual tablet

### Indications

Angina pectoris

## Itraconazole

### Section

#### Antifungal medicines

Oral > Liquid: 10 mg per mL

Oral > Solid: 100 mg

### Indications

Chronic pulmonary aspergillosis

Chromoblastomycosis

Histoplasmosis

Talaromycosis

Sporotrichosis

Paracoccidioidomycosis

## Ivacaftor

### Section

#### Medicines for cystic fibrosis

Oral > Solid > tablet: 75 mg; 150 mg

Oral > Solid > granules: 59.5 mg; 75 mg

### Indications

Cystic fibrosis

## Ivermectin

| Section                                                               | Indications                                                                                                                       |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Intestinal anthelmintics<br>Oral > Solid > tablet: 3 mg               | <div>Strongyloidiasis</div> <div>Ascariasis</div> <div>Trichuriasis</div> <div>Hookworm diseases</div> <div>Ancylostomiasis</div> |
| Medicines for ectoparasitic infections<br>Oral > Solid > tablet: 3 mg | <div>Scabies</div>                                                                                                                |
| Antifilarials<br>Oral > Solid > tablet: 3 mg                          | <div>Lymphatic filariasis</div> <div>Onchocerciasis</div>                                                                         |

## Kanamycin

| Section                                               | Indications                                                                                                                                                                         |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ophthalmological preparations > Anti-infective agents | <div>Therapeutic equivalent to gentamicin for</div> <div>Other specified conjunctivitis</div> <div>Therapeutic equivalent to gentamicin for</div> <div>Infectious blepharitis</div> |

## Kanamycin (injection)

| Section                                                                                                 | Indications                                                |
|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------|
| Antituberculosis medicines<br>Parenteral > General injections > IV: 1000 mg powder for injection (vial) | <div>Multi-drug resistant Mycobacterium tuberculosis</div> |

## Ketamine

| Section                                                                                                                                                                                   | Indications                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| General anaesthetics and oxygen > Injectable medicines<br>Parenteral > General injections > unspecified: 10 mg per mL in vial (as hydrochloride); 50 mg per mL in vial (as hydrochloride) | <div>Anaesthetics and therapeutic gases</div> |

## Ketoconazole

| Section                                                            | Indications                 |
|--------------------------------------------------------------------|-----------------------------|
| Medicines for endocrine disorders<br>Oral > Solid > tablet: 200 mg | <div>Cushing syndrome</div> |

## Lactulose

| Section                                                                                                    | Indications     |
|------------------------------------------------------------------------------------------------------------|-----------------|
| Medicines for other common symptoms in palliative care<br>Oral > Liquid: 3.3 to 3.4 g per 5 mL oral liquid | Palliative care |

## Lamivudine

| Section                                                                                                                                  | Indications                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Liquid: 50 mg per 5 mL<br>Oral > Solid: 150 mg tablet | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Lamivudine + nevirapine + zidovudine

| Section                                                                                                                   | Indications                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Lamivudine + tenofovir

| Section                                    | Indications                                                                                                                                                                                                                                                                                           |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals | Therapeutic equivalent to emtricitabine + tenofovir for<br>Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified<br>Therapeutic equivalent to emtricitabine + tenofovir for<br>Contact with or exposure to human immunodeficiency virus |

## Lamivudine + zidovudine

| Section                                                                                                  | Indications                                                                                                         |
|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Fixed-dose combinations of antiretrovirals<br>Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Lamotrigine

### Section

#### Antiseizure medicines

Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)

### Indications

Epilepsy or seizures

## Latanoprost

### Section

#### Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops

### Indications

Primary open-angle glaucoma

## Ledipasvir + sofosbuvir

### Section

#### Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations

Oral > Solid: 90 mg + 400 mg tablet

### Indications

Chronic hepatitis C

## Lenalidomide

### Section

#### Immunomodulators

Oral > Solid: 25 mg

### Indications

Plasma cell myeloma

## Lenvatinib

### Section

#### Targeted therapies

Oral > Solid > capsule: 4 mg; 10 mg

### Indications

Renal cell carcinoma of kidney, except renal pelvis

## Letrozole

### Section

#### Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

### Indications

Female infertility without specification whether primary or secondary

## Leuprorelin

### Section

#### Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

### Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

## Levamisole

### Section

#### Intestinal anthelmintics

Oral > Solid > tablet: 50 mg (as hydrochloride); 150 mg (as hydrochloride)

### Indications

Ascariasis

## Levetiracetam

### Section

#### Antiseizure medicines

Oral > Liquid: 100 mg per mL

Oral > Solid > tablet: 250 mg; 500 mg; 750 mg; 1000 mg

Parenteral > General injections > IV: 100 mg per mL in 5 mL ampoule or vial; 5 mg per mL in 100 mL bag; 10 mg per mL in 100 mL bag; 15 mg per mL in 100 mL bag

### Indications

Epilepsy or seizures

Status epilepticus

## Levodopa

### Section

#### Medicines for parkinsonism

Oral > Solid: 250 mg

### Indications

Parkinson disease

## Levodopa + benserazide

### Section

#### Medicines for parkinsonism

### Indications

Therapeutic equivalent to levodopa + carbidopa for

Parkinson disease

## Levodopa + carbidopa

### Section

#### Medicines for parkinsonism

Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet

### Indications

Parkinson disease

## Levofloxacin

| Section                                                                                                                         | Indications                                     |
|---------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| <b>Antituberculosis medicines</b><br>Oral > Solid > dispersible tablet: 100 mg<br>Oral > Solid > tablet: 250 mg; 500 mg; 750 mg | Multi-drug resistant Mycobacterium tuberculosis |

## Levonorgestrel

| Section                                                                                               | Indications                                                                                                            |
|-------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| <b>Oral hormonal contraceptives</b><br>Oral > Solid: 750 µg [2]; 1.5 mg [1]<br>Oral > Solid: 30 µg    | Contact with health services for postcoital contraception<br>Contact with health services for contraceptive management |
| <b>Intrauterine devices</b><br>Intrauterine system with reservoir containing 52 mg of levonorgestrel. | Contact with health services for insertion of contraceptive device                                                     |

## Levonorgestrel-releasing implant

| Section                                                                            | Indications                                                        |
|------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| <b>Implantable contraceptives</b><br>Implant > Subdermal: 75 mg per rod (two-rods) | Contact with health services for insertion of contraceptive device |

## Levothyroxine

| Section                                                                                                                           | Indications    |
|-----------------------------------------------------------------------------------------------------------------------------------|----------------|
| <b>Thyroid hormones and antithyroid medicines</b><br>Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt) | Hypothyroidism |

## Lidocaine

| Section                                                                                                                                                                                                                                                                                                                    | Indications                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|
| <b>Antiarrhythmic medicines</b><br>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)                                                                                                                                                                                                      | Ventricular tachyarrhythmia |
| <b>Local anaesthetics</b><br>Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution<br>Parenteral > Locoregional injections > Other: 1% (hydrochloride); 2% (hydrochloride); 0.5% (hydrochloride)<br>Local > Topical > unspecified: 2 to 4% (hydrochloride) | Local anaesthetics          |

## Lidocaine + epinephrine

### Section

#### Local anaesthetics

Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine

Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine

### Indications

Local anaesthetics

## Lindane

### Section

#### Dermatological medicines > Scabicides and pediculicides

Local > Topical > Cream: 1%

Local > Topical > Lotion: 1%

### Indications

Scabies

## Linezolid

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 2 mg per mL in 300 mL bag

Oral > Liquid: 100 mg per 5 mL powder for oral liquid

Oral > Solid: 400 mg tablet; 600 mg tablet

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 600 mg

#### Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg (scored)

Oral > Solid > tablet: 600 mg

### Indications

Other specified bacterial diseases

Methicillin resistant *Staphylococcus aureus*

Vancomycin resistant *Staphylococcus aureus*

Vancomycin resistant *Enterococcus*

Multi-drug resistant *Mycobacterium tuberculosis*

## Liraglutide

### Section

#### Medicines for endocrine disorders

Parenteral > General injections > SC: 6 mg per mL in 3 mL pre-filled pen

#### Hypoglycaemic agents

### Indications

Obesity

Therapeutic equivalent to *semaglutide* for

Obesity

Therapeutic equivalent to *semaglutide* for

Type 2 diabetes mellitus

## Lisinopril + amlodipine

### Section

Antihypertensive medicines

Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg

### Indications

Essential hypertension

## Lisinopril + hydrochlorothiazide

### Section

Antihypertensive medicines

Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg

### Indications

Essential hypertension

## Lisocabtagene maraleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to axicabtagene ciloleucel for

Diffuse large B-cell lymphomas

## Lithium carbonate

### Section

Medicines for bipolar disorders

Oral > Solid: 300 mg

### Indications

Bipolar or related disorders

## Loperamide

### Section

Medicines for other common symptoms in palliative care

Oral > Solid > dosage form: 2 mg

### Indications

Palliative care

## Lopinavir + ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid > tablet: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable)

Oral > Solid > dosage form: 40 mg + 10 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Loratadine

### Section

Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 1 mg per mL

Oral > Solid > tablet: 10 mg; 5 mg (chewable); 10 mg (chewable)

### Indications

Allergic or hypersensitivity conditions of unspecified type

## Lorazepam

| Section                                                                                                                 | Indications                                                     |
|-------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Medicines for anxiety disorders                                                                                         | Therapeutic equivalent to <b>diazepam</b> for<br><b>Anxiety</b> |
| Antiseizure medicines<br>Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule | <b>Status epilepticus</b>                                       |

## Losartan

| Section                                                                                    | Indications                   |
|--------------------------------------------------------------------------------------------|-------------------------------|
| Antihypertensive medicines<br>Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet      | <b>Essential hypertension</b> |
| Medicines used in heart failure<br>Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet | <b>Heart failure</b>          |

## Lovastatin

| Section               | Indications                                                                         |
|-----------------------|-------------------------------------------------------------------------------------|
| Lipid-lowering agents | Therapeutic equivalent to <b>simvastatin</b> for<br><b>Mixed hyperlipidaemia</b>    |
|                       | Therapeutic equivalent to <b>simvastatin</b> for<br><b>Coronary atherosclerosis</b> |

## Magnesium sulfate

| Section                                                                                                                                                                                                                                                             | Indications                                     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Antiseizure medicines<br>Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)<br>Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume) | <b>Severe pre-eclampsia</b><br><b>Eclampsia</b> |

## Malaria vaccine

| Section                                                                                                      | Indications                                                                       |
|--------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Immunologicals > Vaccines<br>All vaccines should comply with the WHO requirements for biological substances. | <b>Need for immunization against certain specified single infectious diseases</b> |

## Mannitol

| Section                                                                       | Indications                                               |
|-------------------------------------------------------------------------------|-----------------------------------------------------------|
| Diuretics<br>Parenteral > General injections > IV: 10% solution; 20% solution | <div>Ocular hypertension</div> <div>Cerebral oedema</div> |

## Measles vaccine

| Section                                                                                                      | Indications                                            |
|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Immunologicals > Vaccines<br>All vaccines should comply with the WHO requirements for biological substances. | <div>Need for immunization against measles alone</div> |

## Mebendazole

| Section                                                                                 | Indications                                                                                        |
|-----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Intestinal anthelmintics<br>Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable) | <div>Ascariasis</div> <div>Enterobiasis</div> <div>Trichuriasis</div> <div>Hookworm diseases</div> |
| Cysticidal medicines<br>Oral > Solid > tablet: 100 mg (chewable); 500 mg (chewable)     | <div>Other specified echinococcosis</div>                                                          |

## Medroxyprogesterone acetate

| Section                                                                                                                                                                                                                                               | Indications                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Injectable hormonal contraceptives<br>Parenteral > General injections > IM: 150 mg per mL in 1 mL vial<br>Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system | <div>Contact with health services for reasons associated with reproduction</div> |
| Progestogens<br>Oral > Solid: 5 mg                                                                                                                                                                                                                    | <div>Excessive menstruation with irregular cycle</div>                           |

## Mefloquine

| Section                                                                                                                            | Indications                                                                                |
|------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Antimalarial medicines > Medicines for curative treatment<br>Oral > Solid: 250 mg tablet (hydrochloride)                           | <div>Malaria due to Plasmodium falciparum</div> <div>Malaria due to Plasmodium vivax</div> |
| Antimalarial medicines > Medicines for chemoprophylaxis in travellers<br>Oral > Solid > tablet: 250 mg (scored) (as hydrochloride) | <div>Malaria due to Plasmodium falciparum</div>                                            |
| Antimalarial medicines > Medicines for chemoprevention<br>Oral > Solid: 250 mg tablet (hydrochloride)                              | <div>Malaria due to Plasmodium falciparum</div>                                            |

## Meglumine antimoniate

| Section                                                                                             | Indications                                                                                                 |
|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Antileishmaniasis medicines<br>Parenteral > General injections > IM: 1.5 g per 5 mL in 5 mL ampoule | <div>Visceral leishmaniasis</div> <div>Cutaneous leishmaniasis</div> <div>Mucocutaneous leishmaniasis</div> |

## Meglumine iotroxate

| Section                                                                                                                          | Indications                                |
|----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| Diagnostic agents > Radiocontrast media<br>Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL | <div>X-ray contrast media, iodinated</div> |

## Melarsoprol

| Section                                                                                                                                                             | Indications                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Medicines for the treatment of 2nd stage African trypanosomiasis<br>Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound) | <div>Rhodesiense trypanosomiasis</div> <div>Gambiense trypanosomiasis</div> |

## Melphalan

| Section                                                                                                               | Indications                    |
|-----------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > IV: 50 mg in vial powder for injection<br>Oral > Solid: 2 mg | <div>Plasma cell myeloma</div> |

## Meningococcal meningitis vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Mercaptopurine

### Section

#### Cytotoxic medicines

Oral > Solid: 50 mg tablet

Oral > Liquid: 20 mg per mL

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Acute myeloid leukaemia with recurrent genetic abnormalities

## Meropenem

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

#### Medicines for bacterial central nervous system infections

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

#### Antituberculosis medicines

Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection

### Indications

#### Second choice

Neutropenia (high-risk)

Peritoneal abscess (severe)

Peritonitis (severe)

Neonatal meningitis

#### Second choice

Neonatal meningitis

Multi-drug resistant *Mycobacterium tuberculosis*

## Meropenem + vaborbactam

### Section

#### Reserve group antibiotics

Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection

### Indications

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

Carbapenem resistant *Acinetobacter baumannii*

## Mesalazine

### Section

Anti-inflammatory medicines

### Indications

Therapeutic equivalent to sulfasalazine for

Crohn disease site

Therapeutic equivalent to sulfasalazine for

Ulcerative colitis

## Mesna

### Section

Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule

Oral > Solid: 400 mg; 600 mg

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule

Oral > Solid > tablet: 400 mg; 600 mg

Oral > Other: 600 mg

Oral > Solid > tablet: 400 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Other specified malignant neoplasms of the ovary

Osteosarcoma of bone and articular cartilage of other specified sites

Burkitt lymphoma including Burkitt leukaemia

Ewing sarcoma of bone and articular cartilage of unspecified sites

Malignant neoplasms of kidney, except renal pelvis

Rhabdomyosarcoma primary site

Germ cell tumour of testis

## Metformin

### Section

Oral hypoglycaemic agents

Oral > Solid: 500 mg (hydrochloride)

### Indications

Type 2 diabetes mellitus

## Methadone

### Section

#### Medicines for opioid use disorders

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

#### Opioid analgesics

Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 25 mg per 5 mL (methadone hydrochloride); 50 mg per 5 mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)

Oral > Solid > tablet: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)

### Indications

Opioid dependence

Chronic cancer pain

## Methimazole

### Section

#### Thyroid hormones and antithyroid medicines

Oral > Solid > tablet: 5 mg; 10 mg

### Indications

Thyrotoxicosis

## Methionine

### Section

#### Antidotes and other substances used in poisonings > Specific

Oral > Solid: 250 mg (DL)

### Indications

Exposure to or harmful effects of undetermined intent of analgesics, antipyretics or nonsteroidal anti-inflammatory drugs

## Methotrexate

| Section                                                                                                                                                                                                                                                                       | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 50 mg in vial (as sodium salt)<br>Oral > Solid: 2.5 mg (as sodium salt)<br>Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Malignant trophoblastic neoplasms of placenta</div> <div>Malignant neoplasms of breast</div> <div>Osteosarcoma of bone and articular cartilage of unspecified sites</div> <div>Anaplastic large cell lymphoma, ALK-negative</div> <div>Anaplastic large cell lymphoma, ALK-positive</div> <div>Langerhans cell histiocytosis</div> <div>Lymphoid leukaemia, not elsewhere classified</div> <div>Acute myeloid leukaemia with recurrent genetic abnormalities</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> |
| <b>Dermatological medicines &gt; Medicines affecting skin differentiation and proliferation</b><br>Oral > Solid > tablet: 2.5 mg (as sodium salt); 10 mg (as sodium salt)                                                                                                     | <div>Psoriasis of unspecified type</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Disease-modifying anti-rheumatic drugs (DMARDs)</b><br>Oral > Solid > tablet: 2.5 mg (as sodium salt)                                                                                                                                                                      | <div>Rheumatoid arthritis, serology unspecified</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Immunomodulators for non-malignant disease</b><br>Parenteral > General injections > SC: pre-filled syringe in multiple strengths                                                                                                                                           | <div>Crohn disease site</div> <div>Psoriatic arthritis</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Medicines for juvenile joint diseases</b><br>Oral > Solid > tablet: 2.5 mg (as sodium salt)                                                                                                                                                                                | <div>Juvenile idiopathic arthritis</div>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## Methoxy polyethylene glycol-epoetin beta

| Section                      | Indications                                                                                                          |
|------------------------------|----------------------------------------------------------------------------------------------------------------------|
| <b>Antianaemia medicines</b> | <div>Therapeutic equivalent to erythropoiesis-stimulating agents for</div> <div>Anaemia due to chronic disease</div> |

## Methyldopa

| Section                                                   | Indications                                                           |
|-----------------------------------------------------------|-----------------------------------------------------------------------|
| <b>Antihypertensive medicines</b><br>Oral > Solid: 250 mg | <div>Essential hypertension</div> <div>Gestational hypertension</div> |

## Methylergometrine

### Section

Uterotonics

### Indications

Therapeutic equivalent to ergometrine for

Postpartum haemorrhage

## Methylphenidate

### Section

Medicines for mental and behavioural disorders

Oral > Solid > tablet: 5 mg (hydrochloride); 10 mg (hydrochloride); 20 mg (hydrochloride); 18 mg extended-release (hydrochloride); 27 mg extended-release (hydrochloride); 36 mg extended-release (hydrochloride); 54 mg extended-release (hydrochloride); 72 mg extended-release (hydrochloride)

Oral > Solid > capsule: 10 to 60 mg extended-release (hydrochloride)

### Indications

Attention deficit hyperactivity disorder

## Methylprednisolone

### Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)

Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

### Indications

Burkitt lymphoma including Burkitt leukaemia

Lymphoid leukaemia, not elsewhere classified

## Methylthioninium chloride

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule

### Indications

Acquired methaemoglobinaemia

## Metoclopramide

| Section                                                                                                                                                                                                                                                    | Indications               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| <p>Medicines for other common symptoms in palliative care</p> <p>Oral &gt; Liquid: 5 mg per 5 mL</p> <p>Oral &gt; Solid: 10 mg (hydrochloride)</p> <p>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)</p> | <p>Palliative care</p>    |
| <p>Antiemetic medicines</p> <p>Oral &gt; Liquid: 5 mg per 5 mL</p> <p>Oral &gt; Solid: 10 mg (scored) (hydrochloride)</p> <p>Parenteral &gt; General injections &gt; unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)</p>                          | <p>Nausea or vomiting</p> |

## Metoprolol

| Section                                | Indications                                                                                   |
|----------------------------------------|-----------------------------------------------------------------------------------------------|
| <p>Antianginal medicines</p>           | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Angina pectoris</p>        |
| <p>Medicines used in heart failure</p> | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Heart failure</p>          |
| <p>Antihypertensive medicines</p>      | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Essential hypertension</p> |
| <p>Antiarrhythmic medicines</p>        | <p>Therapeutic equivalent to <a href="#">bisoprolol</a> for</p> <p>Cardiac arrhythmia</p>     |

## Metronidazole

### Section

#### Access group antibiotics

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Oral > Solid: 200 to 500 mg tablet

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial  
Injection

Local > Rectal > Suppository: 500 mg; 1 g

Parenteral > General injections > unspecified: 500 mg per 100 mL in vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

#### Antiamoebic and anti giardiasis medicines

Oral > Liquid: 200 mg per 5 mL (as benzoate)

Parenteral > General injections > unspecified: 500 mg in 100 mL vial

Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg

### Indications

#### First choice

Intestinal infections due to *Clostridioides difficile*

Trichomoniasis

co-prescribed with cefazolin

Other specified prophylactic measures

co-prescribed with cefotaxime

Peritonitis (severe)

co-prescribed with cefotaxime

Peritonitis (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (mild-moderate)

co-prescribed with cefotaxime

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Necrotising fasciitis

co-prescribed with ceftriaxone

Peritonitis (severe)

co-prescribed with ceftriaxone

Peritoneal abscess (mild-moderate)

co-prescribed with ceftriaxone

Peritoneal abscess (severe)

co-prescribed with ceftriaxone

Peritonitis (mild-moderate)

#### Second choice

co-prescribed with ciprofloxacin

Peritonitis (mild-moderate)

co-prescribed with ciprofloxacin

Peritoneal abscess (mild-moderate)

#### Other indications

Bacterial infection of unspecified site

Amoebiasis

## Micafungin

### Section

[Antifungal medicines](#)

Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection

### Indications

Systemic or invasive candidosis

## Miconazole

### Section

[Dermatological medicines](#) > [Antifungal medicines](#)

Local > Topical > Cream: 2% (nitrate)

Local > Topical > Ointment: 2% (nitrate)

### Indications

Fungal infection of the skin

## Midazolam

### Section

#### Antiseizure medicines

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial (for buccal administration); 5 mg per mL in 1 mL vial (for buccal administration); 5 mg per mL in 3 mL vial (for buccal administration)

Local > Buccal > Solution: 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe; 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

#### Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial

Oral > Liquid: 2 mg per mL

Oral > Solid > dosage form: 15 mg; 7.5 mg

#### Medicines for other common symptoms in palliative care

Oral > Liquid: 2 mg per mL

Parenteral > General injections > unspecified: 1 mg per mL in 5 mL vial; 5 mg per mL in 1 mL vial; 5 mg per mL in 3 mL vial

Local > Buccal > Solution: ; 5 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 1.5 mL pre-filled syringe (for oromucosal administration); 5 mg per mL in 2 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.25 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.5 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 0.75 mL pre-filled syringe (for oromucosal administration); 10 mg per mL in 1 mL pre-filled syringe (for oromucosal administration)

Oral > Solid > dosage form: 7.5 mg; 15 mg

### Indications

Status epilepticus

Therapeutic equivalent to lorazepam for

Status epilepticus

Sedative-hypnotic and anxiolytic drugs

Palliative care

## Mifepristone - misoprostol

### Section

#### Medicines for medical abortion

Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

### Indications

Unspecified time of fetal death, cause not specified

Induced abortion

## Miltefosine

### Section

Antileishmaniasis medicines

Oral > Solid: 10 mg; 50 mg

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Misoprostol

### Section

Uterotonics

Local > Vaginal > tablet: 25 µg

Oral > Solid: 200 µg

Medicines for medical abortion

Oral > Solid > tablet: 200 µg

### Indications

Unspecified obstetric condition

Postpartum haemorrhage

Spontaneous abortion, incomplete, without complication

## Mometasone

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide** for

Asthma

## Mometasone + formoterol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to **budesonide + formoterol** for

Asthma

## Morphine

### Section

#### Preoperative medication and sedation for short-term procedures

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

#### Opioid analgesics

Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate); 5 mg per 5 mL (morphine hydrochloride or morphine sulfate)

Parenteral > General injections > unspecified: 1 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 2 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate); 10 mg per mL in 1 mL ampoule (morphine hydrochloride or morphine sulfate)

Oral > Solid > tablet: 10 mg immediate release (morphine sulfate)

Oral > Solid > dosage form: 5 mg slow-release (morphine hydrochloride or morphine sulfate); 10 mg slow-release (morphine hydrochloride or morphine sulfate); 30 mg slow-release (morphine hydrochloride or morphine sulfate); 60 mg slow-release (morphine hydrochloride or morphine sulfate); 100 mg slow-release (morphine hydrochloride or morphine sulfate); 200 mg slow-release (morphine hydrochloride or morphine sulfate)

Oral > Solid > granules: 20 mg (morphine sulfate); 30 mg (morphine sulfate); 60 mg (morphine sulfate); 100 mg (morphine sulfate); 200 mg (morphine sulfate)

### Indications

Opioids or related analgesics and agents affecting opioid receptors

Pain

## Moxidectin

### Section

#### Antifilarials

Oral > Solid > tablet: 2 mg

### Indications

Therapeutic equivalent to ivermectin for

Lymphatic filariasis

Therapeutic equivalent to ivermectin for

Onchocerciasis

## Moxifloxacin

### Section

#### Antituberculosis medicines

Oral > Solid > tablet: 400 mg

Oral > Solid > dispersible tablet: 100 mg

### Indications

Tuberculosis

Multi-drug resistant Mycobacterium tuberculosis

## Mpox vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Multiple micronutrient powder

### Section

#### Vitamins and minerals

Sachets containing:

- iron (elemental) 12.5 mg (as coated ferrous fumarate)
- zinc (elemental) 5 mg
- vitamin A 300 micrograms
- with or without other micronutrients at recommended daily values

### Indications

Iron deficiency anaemia

## Multiple micronutrient supplement

### Section

#### Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

### Indications

Maternal care for other specified conditions predominantly related to pregnancy

## Mumps vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against mumps alone

## Mupirocin

### Section

Dermatological medicines > Anti-infective medicines

Local > Topical > Cream: 2% (as mupirocin calcium)

Local > Topical > Ointment: 2%

### Indications

Superficial bacterial folliculitis

Impetigo

## Nadroparin

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to enoxaparin for

Acute ischaemic heart disease

Therapeutic equivalent to enoxaparin for

Venous thromboembolism

## Nalidixic acid

### Section

Anti-infective medicines

Oral > Solid: 250 mg; 500 mg

### Indications

Shigella resistant to unspecified antibiotic

## Naloxone

### Section

Antidotes and other substances used in poisonings > Specific

Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)

### Indications

Unintentional exposure to or harmful effects of opioids or related analgesics

## Naltrexone

### Section

Medicines for alcohol use disorders

Parenteral > General injections > IM: 380 mg in vial (extended-release)

Oral > Solid > tablet: 50 mg

### Indications

Disorders due to use of alcohol

## Naproxen

### Section

Medicines for acute migraine attacks

### Indications

Therapeutic equivalent to [ibuprofen](#) for

Migraine

## Natamycin

### Section

Ophthalmological preparations > Anti-infective agents  
Local > Ophthalmological > Suspension: 5% eye drops

### Indications

Infectious keratitis

## Nelfinavir

### Section

Antiretrovirals > Protease inhibitors  
Oral > Solid: 250 mg (as mesilate)  
Oral > Other: 50 mg per g oral powder

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Neostigmine

### Section

Medicines for myasthenia gravis  
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)  
Oral > Solid > tablet: 15 mg (neostigmine bromide)

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors  
Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)  
Oral > Solid > tablet: 15 mg (neostigmine bromide)

### Indications

Myasthenia gravis

Myasthenia gravis

Anticholinesterase reversible

## Netilmicin

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to [gentamicin](#) for

Other specified conjunctivitis

Therapeutic equivalent to [gentamicin](#) for

Infectious blepharitis

## Nevirapine

### Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > dispersible tablet: 50 mg

Oral > Solid > tablet: 200 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Niclosamide

### Section

Intestinal anthelmintics

Oral > Solid: 500 mg tablet (chewable)

### Indications

Hymenolepiasis

Diphyllobothriasis

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

## Nicotinamide

### Section

Vitamins and minerals

Oral > Solid: 50 mg

### Indications

Pellagra

## Nicotine replacement therapy

### Section

Medicines for nicotine use disorders

Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour

Oral > Solid > lozenge: 2 mg; 4 mg lozenge

Local > Buccal > Oral spray: 1 mg per actuation

Local > Buccal > Chewing gum: 2 mg; 4 mg

### Indications

Nicotine dependence

## Nifedipine

### Section

Antioxytocs (tocolytics)

Oral > Solid: 10 mg (immediate-release)

Antianginal medicines

Oral > Solid: 10 mg

Antihypertensive medicines

Oral > Solid: 10 mg tablet; sustained-release formulations

### Indications

Preterm labour without delivery

Angina pectoris

Essential hypertension

## Nifurtimox

| Section                                                                                                                    | Indications               |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------|
| American trypanosomiasis<br>Oral > Solid > tablet: 30 mg (scored); 120 mg (scored)                                         | Chagas disease            |
| Medicines for the treatment of 2nd stage African trypanosomiasis<br>Oral > Solid > tablet: 30 mg (scored); 120 mg (scored) | Gambiense trypanosomiasis |

## Nilotinib

| Section                                                      | Indications                                         |
|--------------------------------------------------------------|-----------------------------------------------------|
| Targeted therapies<br>Oral > Solid > capsule: 150 mg; 200 mg | Chronic myeloid leukaemia, not elsewhere classified |

## Nilutamide

| Section                   | Indications                                                                   |
|---------------------------|-------------------------------------------------------------------------------|
| Hormones and antihormones | Therapeutic equivalent to bicalutamide for<br>Malignant neoplasms of prostate |

## Nitrofurantoin

| Section                                                                                                            | Indications                         |
|--------------------------------------------------------------------------------------------------------------------|-------------------------------------|
| Access group antibiotics<br>Oral > Liquid: 25 mg per 5 mL oral liquid<br>Oral > Solid > dosage form: 100 mg; 50 mg | First choice<br>Infectious cystitis |

## Nitrous oxide

| Section                                                                               | Indications                        |
|---------------------------------------------------------------------------------------|------------------------------------|
| General anaesthetics and oxygen > Inhalational medicines<br>Respiratory > Inhalation: | Anaesthetics and therapeutic gases |

## Nivolumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion

Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

### Indications

Therapeutic equivalent to pembrolizumab for

Melanoma of skin

Other specified malignant neoplasms of bronchus or lung

Melanoma of skin

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of oesophagus

Adenocarcinoma of oesophagogastric junction

Adenocarcinoma of stomach

## Norethisterone

### Section

#### Oral hormonal contraceptives

Oral > Solid: 350 µg

#### Progestogens

Oral > Solid: 5 mg

### Indications

Contact with health services for contraceptive management

Excessive menstruation with irregular cycle

Therapeutic equivalent to medroxyprogesterone acetate for

Excessive menstruation with irregular cycle

## Norethisterone enantate

### Section

#### Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

### Indications

Contact with health services for reasons associated with reproduction

## Normal immunoglobulin

| Section                                                                                                                                                                                                                                                                                                                                                                                                          | Indications                                                                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Human immunoglobulins</b><br>Parenteral > General injections > IV: 5% protein solution; 10% protein solution<br><br>Parenteral > General injections > IM: 16% protein solution<br><br>Parenteral > General injections > SC: 15% protein solution; 16% protein solution<br><br><b>Medicines for Guillain-Barré syndrome</b><br>Parenteral > General injections > IV: 5% protein solution; 10% protein solution | <div>Primary immunodeficiencies</div> <div>Langerhans cell histiocytosis</div> <div>Mucocutaneous lymph node syndrome</div><br><div>Acute inflammatory demyelinating polyneuropathy</div> |

## Nystatin

| Section                                                                                                                                                                                                | Indications           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| <b>Antifungal medicines</b><br>Oral > Liquid: 100000 IU per mL<br><br>Local > Topical > Other: 100000 IU pessary<br><br>Oral > Solid > dosage form: 500000 IU<br><br>Oral > Solid > lozenge: 100000 IU | <div>Candidosis</div> |

## Ocrelizumab

| Section                                                                                                                                                                                                   | Indications                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| <b>Medicines for multiple sclerosis</b><br>Parenteral > General injections > IV: 30 mg per mL in 10 mL vial<br><br>Parenteral > General injections > IV: 30 mg per mL in 10 vial concentrate for solution | <div>Relapsing-remitting multiple sclerosis</div> <div>Multiple sclerosis</div> |

## Octreotide

| Section                                                                                                                                                                                                                                                                                                                                                                                            | Indications                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------|
| <b>Medicines for disorders of the pituitary hormone system</b><br>Parenteral > General injections > IM: 20 mg in vial (modified-release, as acetate) plus diluent<br><br>Parenteral > General injections > SC: 0.05 mg per mL in 1 mL vial (immediate-release, as acetate); 0.1 mg per mL in 1 mL vial (immediate-release, as acetate); 0.5 mg per mL in 1 mL vial (immediate-release, as acetate) | <div>Acromegaly or pituitary gigantism</div> |

## Ofloxacin

| Section                                                                                                        | Indications                                                                        |
|----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Antituberculosis medicines<br>Oral > Solid: 200 mg; 400 mg                                                     | Multi-drug resistant Mycobacterium tuberculosis                                    |
| Ear, nose and throat medicines [c]                                                                             | Therapeutic equivalent to ciprofloxacin for<br>Infectious diseases of external ear |
| Ophthalmological preparations > Anti-infective agents<br>Local > Ophthalmological > Solution (eye drops): 0.3% | Other specified conjunctivitis<br>Infectious keratitis                             |

## Olanzapine

| Section                                                                                                       | Indications                                                                                                                                           |
|---------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Medicines for psychotic disorders<br>Parenteral > General injections > IM: 10 mg in vial powder for injection | Therapeutic equivalent to risperidone for<br>Schizophrenia or other primary psychotic disorders<br>Schizophrenia or other primary psychotic disorders |

## Omadacycline

| Section                                                                                                                            | Indications                                 |
|------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| Reserve group antibiotics<br>Parenteral > General injections > IV: 100 mg lyophilized powder for injection<br>Oral > Solid: 300 mg | Methicillin resistant Staphylococcus aureus |

## Ombitasvir + paritaprevir + ritonavir

| Section                                                                                                                           | Indications         |
|-----------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations<br>Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet | Chronic hepatitis C |

## Omeprazole

### Section

#### Antiulcer medicines

Parenteral > General injections > IV: 40 mg in vial

Oral > Liquid: 1 mg per mL powder for oral liquid; 4 mg per mL powder for oral liquid

Oral > Solid > dosage form: 10 mg; 20 mg; 40 mg

### Indications

Gastrointestinal bleeding

Peptic ulcer, site unspecified

Gastro-oesophageal reflux disease

## Ondansetron

### Section

#### Medicines for other common symptoms in palliative care

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule (as hydrochloride dihydrate)

Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)

Oral > Solid: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate)

#### Antiemetic medicines

Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (as hydrochloride dihydrate); 2 mg per mL in 4 mL ampoule

Oral > Liquid: 4 mg per 5 mL (as hydrochloride dihydrate)

Oral > Solid > dosage form: 4 mg (as hydrochloride dihydrate); 8 mg (as hydrochloride dihydrate); 24 mg (as hydrochloride dihydrate)

### Indications

Palliative care

Nausea or vomiting

## Oral rehydration salts

### Section

Solutions correcting water, electrolyte and acid-base disturbances > Oral

Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq or mmol/L
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mEq or mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L

### Oral rehydration

Powder for dilution in 200 mL, 500 mL, 1 L:

- glucose 75 mEq or mmol/L
- sodium 75 mEq or mmol/L
- chloride 65 mEq or mmol/L
- potassium 20 mEq or mmol/L
- citrate 10 mEq or mmol/L
- osmolarity 245 mOsm/L
- glucose 13.5 g/L
- sodium chloride 2.6 g/L
- potassium chloride 1.5 g/L
- trisodium citrate dihydrate 2.9 g/L

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

Diarrhoea

## Oral rehydration salts - zinc sulfate

### Section

### Medicines used in diarrhoea

Oral > Other: ORS powder for dilution and zinc sulfate dispersible tablet  
20 mg (co-packaged)

### Indications

Diarrhoea

## Oseltamivir

### Section

#### Other antivirals

Oral > Liquid: 6 mg per mL (as phosphate) powder for oral liquid

Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)

### Indications

Influenza due to identified seasonal influenza virus

## Osimertinib

### Section

#### Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

### Indications

Other specified malignant neoplasms of bronchus or lung

## Oxaliplatin

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

### Indications

Malignant neoplasm metastasis in large intestine

Malignant neoplasms of colon

## Oxamniquine

### Section

#### Antischistosomes and other antitremaatode medicines

Oral > Liquid: 250 mg per 5 mL

Oral > Solid > capsule: 250 mg

### Indications

Schistosomiasis due to *Schistosoma mansoni*

## Oxazolindinones

### Section

#### Reserve group antibiotics

.

### Indications

Other specified bacterial diseases

## Oxycodone

### Section

#### Opioid analgesics

### Indications

Therapeutic equivalent to morphine for

Pain

## Oxygen

### Section

General anaesthetics and oxygen > Inhalational medicines  
Respiratory > Inhalation: (medical gas)

Medical gases

Respiratory > Inhalation:

### Indications

Anaesthetics and therapeutic gases

Respiratory failure as acute or chronic

## Oxytetracycline

### Section

Ophthalmological preparations > Anti-infective agents

### Indications

Therapeutic equivalent to tetracycline for

Other specified conjunctivitis

Therapeutic equivalent to tetracycline for

Infectious keratitis

Therapeutic equivalent to tetracycline for

Infectious blepharitis

Therapeutic equivalent to tetracycline for

Trachoma

## Oxytocin

### Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

### Indications

Postpartum haemorrhage

## P-aminosalicylate sodium

### Section

Antituberculosis medicines

Oral > Liquid: 5.52 g in sachet (equivalent to 4 g p-aminosalicylic acid)  
powder for oral solution

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## P-aminosalicylic acid

### Section

Antituberculosis medicines

Oral > Solid: 4 g granules in sachet

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Paclitaxel

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 6 mg per mL

### Indications

Other specified malignant neoplasms of the ovary

Other specified malignant neoplasms of bronchus or lung

Malignant neoplasms of nasopharynx

Kaposi sarcoma of unspecified primary site

Other specified malignant neoplasms of breast

Other specified carcinomas of ovary

Malignant neoplasms of breast

Malignant neoplasms of cervix uteri

## Palbociclib

### Section

#### Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

### Indications

Other specified malignant neoplasms of breast

## Paliperidone

### Section

#### Medicines for psychotic disorders

Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)

### Indications

Therapeutic equivalent to risperidone for

Schizophrenia or other primary psychotic disorders

Schizophrenia or other primary psychotic disorders

## Palonosetron

### Section

#### Medicines for other common symptoms in palliative care

#### Antiemetic medicines

### Indications

Therapeutic equivalent to ondansetron for

Palliative care

Therapeutic equivalent to ondansetron for

Nausea or vomiting

## Pancreatic enzymes

| Section                                                                                                                                                                                                                                            | Indications              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <p><b>Gastrointestinal medicines</b></p> <p>Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.</p> <p>*Units expressed in Ph. Eur</p>    | <p>Enzyme intestinal</p> |
| <p><b>Medicines for cystic fibrosis</b></p> <p>Capsule (modified release): 10 000 lipase units + 8000 amylase units + 600 protease units; 25 000 lipase units + 18 000 amylase units + 1000 protease units.</p> <p>*Units expressed in Ph. Eur</p> | <p>Cystic fibrosis</p>   |

## Panitumumab

| Section                                                                                                                                                                         | Indications                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|
| <p><b>Targeted therapies</b></p> <p>Parenteral &gt; General injections &gt; IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial</p> | <p>Other specified malignant neoplasms of large intestine</p> |

## Paracetamol (acetaminophen)

| Section                                                                                                                                                                                                                                                                                                                                         | Indications     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| <p><b>Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)</b></p> <p>Oral &gt; Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL</p> <p>Local &gt; Rectal &gt; Suppository: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; dispersible tablet: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; tablet: 250 mg; 325 mg; 500 mg</p> | <p>Pain</p>     |
| <p><b>Medicines for acute migraine attacks</b></p> <p>Oral &gt; Liquid: 125 mg per 5 mL; 120 mg per 5 mL; 250 mg per 5 mL</p> <p>Local &gt; Rectal &gt; Suppository: 250 mg</p> <p>Oral &gt; Solid &gt; dispersible tablet: 100 mg; 250 mg</p> <p>Oral &gt; Solid &gt; tablet: 250 mg; 325 mg; 500 mg</p>                                       | <p>Migraine</p> |

## Paromomycin

### Section

#### Antileishmaniasis medicines

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

#### Antiamoebic and anti giardiasis medicines

Oral > Liquid: 125 mg per 5 mL as sulfate

Oral > Solid: 250 mg as sulfate

### Indications

Visceral leishmaniasis

Amoebiasis

## Pegaspargase

### Section

#### Cytotoxic medicines

Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

### Indications

Lymphoid leukaemia, not elsewhere classified

## Pegfilgrastim

### Section

#### Immunomodulators

Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

### Indications

Acquired neutropaenia

## Pegylated interferon alfa (2a)

### Section

#### Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pegylated interferon alfa (2b)

### Section

#### Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

### Indications

Chronic hepatitis C

## Pembrolizumab

### Section

#### Immunomodulators

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection

Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

### Indications

Melanoma of skin

Malignant neoplasms of cervix uteri

Other specified malignant neoplasms of large intestine

Other specified malignant neoplasms of bronchus or lung

Adenocarcinoma of stomach

Squamous cell carcinoma of hypopharynx and variants

Renal cell carcinoma of kidney, except renal pelvis

Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx

Squamous cell carcinoma of oropharynx

Carcinoma of breast, specialised type

Squamous cell carcinoma of nasopharynx

Squamous cell carcinoma of oesophagus

Malignant neoplasms of oesophagogastric junction

Therapeutic equivalent to nivolumab for

Melanoma of skin

## Penicillamine

### Section

Antidotes and other substances used in poisonings > Specific

Oral > Solid: 250 mg

Disease-modifying anti-rheumatic drugs (DMARDs)

Oral > Solid: 250 mg

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

Rheumatoid arthritis, serology unspecified

## Pentamidine

| Section                                                                                                                                                                       | Indications               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| <a href="#">Antileishmaniasis medicines</a><br>Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)                                           | Visceral leishmaniasis    |
| <a href="#">Antipneumocystosis and antitoxoplasmosis medicines</a><br>Oral > Solid > tablet: 200 mg (as isethionate); 300 mg (as isethionate)                                 | Pneumocystosis            |
| <a href="#">Medicines for the treatment of 1st stage African trypanosomiasis</a><br>Parenteral > General injections > IM: 300 mg in vial (as isetionate) powder for injection | Gambiense trypanosomiasis |

## Perindopril + amlodipine + indapamide

| Section                                                                                                                                                                                                            | Indications            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| <a href="#">Antihypertensive medicines</a><br>Oral > Solid > dosage form: 5 mg (arginine) + 5 mg + 1.25 mg; 5 mg (arginine) + 10 mg + 1.25 mg; 10 mg (arginine) + 5 mg + 2.5 mg; 10 mg (arginine) + 10 mg + 2.5 mg | Essential hypertension |

## Permethrin

| Section                                                                                                                                   | Indications                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| <a href="#">Dermatological medicines &gt; Scabicides and pediculicides</a><br>Local > Topical > Lotion: 1%<br>Local > Topical > Cream: 5% | Pediculosis corporis<br>Pediculosis capitis<br>Scabies |

## Pertussis vaccine

| Section                                                                                                                         | Indications                                   |
|---------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| <a href="#">Immunologicals &gt; Vaccines</a><br>All vaccines should comply with the WHO requirements for biological substances. | Need for immunization against pertussis alone |

## Pertuzumab

| Section                                                                                                                    | Indications                           |
|----------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| <a href="#">Targeted therapies</a><br>Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution | Carcinoma of breast, specialised type |

## Phenelzine

### Section

Medicines for depressive disorders

Oral > Solid > dosage form: 15 mg (as sulfate)

### Indications

Other specified depressive disorders

## Phenobarbital

### Section

Antiseizure medicines

Parenteral > General injections > IV: 200 mg per mL (phenobarbital sodium); 30 mg per mL (phenobarbital sodium); 60 mg per mL (phenobarbital sodium)

Oral > Liquid: 15 mg per 5 mL

Oral > Solid > tablet: 15 mg; 30 mg; 60 mg; 100 mg

### Indications

Status epilepticus

Epilepsy or seizures

## Phenoxymethylpenicillin

### Section

Access group antibiotics

Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid

Oral > Solid: 250 mg (as potassium salt) tablet

Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)

### Indications

#### First choice

Acute pharyngitis

Periapical abscess without sinus

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

#### Other indications

Bacterial infection of unspecified site

## Phenytoin

### Section

Antiseizure medicines

Oral > Liquid: 30 mg per 5 mL (phenytoin)

Parenteral > General injections > unspecified: 50 mg per mL in vial (phenytoin sodium)

Oral > Solid > tablet: 50 mg (phenytoin) (chewable)

Oral > Solid > dosage form: 25 mg (phenytoin sodium); 50 mg (phenytoin sodium); 100 mg (phenytoin sodium)

### Indications

Epilepsy or seizures

## Phosphorus

### Section

#### Medicines for endocrine disorders

Oral > Other: 500 mg in sachet (elemental phosphorus) granules

Oral > Solid > tablet: 250 mg (elemental phosphorus); 500 mg (elemental phosphorus); 500 mg (elemental phosphorus) (effervescent)

### Indications

Hypophosphataemic rickets

## Phytomenadione

### Section

#### Medicines affecting coagulation

Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution

Oral > Solid > tablet: 5 mg tablet

### Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

Haemorrhagic or haematological disorders of fetus or newborn

## Pilocarpine

### Section

#### Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)

### Indications

Acute angle closure with pupillary block

Ocular hypertension

Primary open-angle glaucoma

## Piperacillin + tazobactam

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection

### Indications

#### First choice

Peritoneal abscess (severe)

Other specified pneumonia (Hospital-acquired pneumonia)

Neutropenia (high-risk)

Peritonitis (severe)

co-prescribed with clindamycin

Necrotising fasciitis

## Platelets

### Section

#### Blood and blood components

Parenteral > General injections > IV:

### Indications

Blood transfusion without reported diagnosis

## Plazomicin

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 500 mg per 10 mL

### Indications

Carbapenem resistant *Acinetobacter baumannii*

Carbapenem-resistant *Pseudomonas aeruginosa*

Carbapenem resistant Enterobacterales

## Pneumococcal vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against single bacterial diseases

## Podophyllotoxin

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to [podophyllum resin](#) for

Anogenital warts

Therapeutic equivalent to [podophyllum resin](#) for

Plantar warts

## Podophyllum resin

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 10 to 25%

### Indications

Anogenital warts

Plantar warts

## Poliomyelitis vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against poliomyelitis

## Polygeline

| Section                                                                                                                                                        | Indications                                                                                                              |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Plasma substitutes</a><br>Parenteral > General injections > IV: 3.5% injectable solution<br>Parenteral > General injections > IV: 3.5% in solution | Therapeutic equivalent to <a href="#">dextran 70</a> for<br><a href="#">Hypovolaemia</a><br><a href="#">Hypovolaemia</a> |

## Polymyxin B (injection)

| Section                                                                                                                                                          | Indications                                                                                                                                                                          |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <a href="#">Reserve group antibiotics</a><br>Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base) | <a href="#">Carbapenem resistant Acinetobacter baumannii</a><br><a href="#">Carbapenem-resistant Pseudomonas aeruginosa</a><br><a href="#">Carbapenem resistant Enterobacterales</a> |

## Polymyxins

| Section                                        | Indications                                        |
|------------------------------------------------|----------------------------------------------------|
| <a href="#">Reserve group antibiotics</a><br>. | <a href="#">Other specified bacterial diseases</a> |

## Porcatant alfa

| Section                                                                                                                            | Indications                                              |
|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| <a href="#">Medicines administered to the neonate [c]</a><br>Respiratory > Suspension: 80 mg per mL for intratracheal instillation | <a href="#">Respiratory distress syndrome of newborn</a> |

## Potassium chloride

| Section                                                                                                                                                                                                                                                                                                                                                                    | Indications                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|
| <a href="#">Solutions correcting water, electrolyte and acid-base disturbances &gt; Oral</a><br>Oral > Liquid: powder for solution                                                                                                                                                                                                                                         | <a href="#">Hypokalaemia</a> |
| <a href="#">Solutions correcting water, electrolyte and acid-base disturbances &gt; Parenteral</a><br>Parenteral > General injections > IV: 11.2% in 20 mL ampoule (equivalent to K+ 1.5 mmol/mL and Cl- 1.5 mmol/mL); 7.5% solution for dilution (equivalent to K+ 1 mmol/mL and Cl- 2 mmol/mL); 15% solution for dilution (equivalent to K+ 2 mmol/mL and Cl- 2 mmol/mL) | <a href="#">Hypokalaemia</a> |

## Potassium ferric hexacyanoferrate (Prussian blue)

### Section

Antidotes and other substances used in poisonings > Specific  
Oral > Solid: Powder for oral administration

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Potassium iodide

### Section

Antifungal medicines  
Local > Topical > Solution: Saturated solution  
  
Thyroid hormones and antithyroid medicines  
Oral > Solid > tablet: 65 mg (scored)

### Indications

Sporotrichosis

Thyrotoxicosis

## Potassium permanganate

### Section

Dermatological medicines > Anti-infective medicines  
Local > Topical > Solution: aqueous solution: 1:10 000

### Indications

Tropical phagedaenic ulcer

Pemphigus

Other specified pyogenic bacterial infection of skin and subcutaneous tissue

Impetigo

## Povidone iodine

### Section

Antiseptics  
Local > Topical > Solution: 10% (equivalent to 1% available iodine)

### Indications

Povidone iodine

## Pralidoxime

### Section

Antidotes and other substances used in poisonings > Specific  
.

### Indications

Exposure to or harmful effects of undetermined intent of pesticides

## Pramipexole

### Section

#### Antiseizure medicines

Oral > Solid: 125 µg immediate-release; 250 mg immediate-release; 500 µg immediate-release; 750 µg immediate-release; 1 mg immediate-release; 1.5 mg immediate-release; 375 µg extended-release; 750 µg extended-release; 1.5 mg extended-release; 2.25 mg extended-release; 3 mg extended-release; 3.75 mg extended-release; 4.5 extended-release

### Indications

Parkinson disease

## Pravastatin

### Section

#### Lipid-lowering agents

### Indications

Therapeutic equivalent to [simvastatin](#) for

Mixed hyperlipidaemia

Therapeutic equivalent to [simvastatin](#) for

Coronary atherosclerosis

## Praziquantel

### Section

#### Antischistosomes and other antitrematode medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

### Indications

Paragonimiasis

Clonorchiasis

Opisthorchiasis

Schistosomiasis

#### Intestinal anthelmintics

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Taeniasis due to *Taenia saginata*

Taeniasis due to *Taenia solium*

Hymenolepiasis

Diphyllobothriasis

#### Cysticidal medicines

Oral > Solid > tablet: 600 mg (scored); 500 mg; 150 mg

Cysticercosis of central nervous system

## Precipitated sulfur

### Section

[Dermatological medicines](#) > [Scabicides and pediculicides](#)

Local > Topical > Ointment:

### Indications

Therapeutic equivalent to [benzyl benzoate](#) for

[Pthiriasis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Pediculosis corporis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Pediculosis capitis](#)

Therapeutic equivalent to [benzyl benzoate](#) for

[Scabies](#)

## Prednisolone

### Section

#### Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

#### Anti-inflammatory medicines

Local > Rectal > Retention enema:

Local > Rectal > Retention enema: 20 mg per 100 mL (as sodium phosphate)

#### Antiallergics and medicines used in anaphylaxis

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

#### Ophthalmological preparations > Anti-inflammatory agents

Local > Ophthalmological > Solution (eye drops): 0.5% (sodium phosphate)

#### Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

#### Medicines for cluster headache

Oral > Solid > tablet: 25 mg; 5 mg

#### Antiseizure medicines

Oral > Liquid: 1 mg per mL

Oral > Solid > tablet: 1 mg; 5 mg; 10 mg

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Malignant neoplasms of prostate

Hodgkin lymphoma

Anaplastic large cell lymphoma, ALK-negative

Anaplastic large cell lymphoma, ALK-positive

Langerhans cell histiocytosis

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Therapeutic equivalent to hydrocortisone for

Crohn disease site

Crohn disease site

Ulcerative colitis

Allergic or hypersensitivity conditions of unspecified type

Scleritis

Anterior uveitis

Adrenocortical insufficiency

Trigeminal autonomic cephalalgias

Infantile spasms

## Prednisone

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to prednisolone for

Plasma cell myeloma

Therapeutic equivalent to prednisolone for

Follicular lymphoma

Therapeutic equivalent to prednisolone for

Malignant neoplasms of prostate

Therapeutic equivalent to prednisolone for

Hodgkin lymphoma

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-negative

Therapeutic equivalent to prednisolone for

Anaplastic large cell lymphoma, ALK-positive

Therapeutic equivalent to prednisolone for

Langerhans cell histiocytosis

Therapeutic equivalent to prednisolone for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to prednisolone for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to prednisolone for

Diffuse large B-cell lymphoma, not otherwise specified

Antiallergics and medicines used in anaphylaxis

Therapeutic equivalent to prednisolone for

Allergic or hypersensitivity conditions of unspecified type

Adrenal hormones and synthetic substitutes

Oral > Solid > tablet: 1 mg

Therapeutic equivalent to prednisolone for

Adrenocortical insufficiency

## Pretomanid

### Section

Antituberculosis medicines

Oral > Solid > tablet: 200 mg

### Indications

Multi-drug resistant Mycobacterium tuberculosis

## Primaquine

### Section

Antimalarial medicines > Medicines for curative treatment

Oral > Solid > tablet: 7.5 mg (as phosphate); 15 mg (as phosphate)

### Indications

Malaria due to *Plasmodium ovale*

Malaria due to *Plasmodium falciparum*

Malaria due to *Plasmodium vivax*

## Probenecid

### Section

Medicines used to treat gout

Oral > Solid: 500 mg

### Indications

Gout

## Procainamide

### Section

Antiarrhythmic medicines

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule (hydrochloride)

Oral > Solid: 500 mg (hydrochloride); 250 mg (hydrochloride)

### Indications

Cardiac arrhythmia

## Procaine benzylpenicillin

### Section

Access group antibiotics

Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection

### Indications

#### First choice

Congenital syphilis [children]

#### Second choice

Syphilis

## Procarbazine

### Section

Cytotoxic medicines

Oral > Solid: 50 mg (as hydrochloride)

Oral > Solid > capsule: 50 mg (as hydrochloride)

### Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Hodgkin lymphoma

## Progesterone vaginal ring

### Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

### Indications

Contact with health services for contraceptive management

## Proguanil

### Section

Antimalarial medicines > Medicines for chemoprevention  
Oral > Solid: 100 mg tablet (hydrochloride)

### Indications

Malaria due to *Plasmodium falciparum*

## Promethazine

### Section

Antiemetic medicines  
Oral > Liquid: 5 mg per 5 mL (hydrochloride)  
Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)  
Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule

### Indications

Nausea or vomiting

## Propanol

### Section

Antiseptics

### Indications

Therapeutic equivalent to [ethanol](#) for

Denatured alcohol

## Propofol

### Section

General anaesthetics and oxygen > Injectable medicines  
Parenteral > General injections > IV: 10 mg per mL; 20 mg per mL

### Indications

Anaesthetics and therapeutic gases

## Propranolol

### Section

Antihypertensive medicines  
Oral > Solid: 80 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antianginal medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Antiarrhythmic medicines

Parenteral > General injections > IV: 1 mg in 1 mL ampoule (hydrochloride)

Oral > Solid: 10 mg tablet (hydrochloride); 40 mg tablet (hydrochloride)

Medicines for migraine prophylaxis

Oral > Solid > tablet: 40 mg (hydrochloride); 10 mg (hydrochloride)

### Indications

Essential hypertension

Angina pectoris

Cardiac arrhythmia

Migraine

## Propylthiouracil

### Section

Thyroid hormones and antithyroid medicines

Oral > Solid: 50 mg

### Indications

Thyrotoxicosis

## Protamine sulfate

### Section

Medicines affecting coagulation

Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

### Indications

Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors

## Protonamide

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to ethionamide for

Multi-drug resistant *Mycobacterium tuberculosis*

## Pyrantel

### Section

Intestinal anthelmintics

Oral > Solid > tablet: 250 mg (chewable) (as embonate or pamoate)

### Indications

Ascariasis

Trichuriasis

Enterobiasis

Hookworm diseases

## Pyrazinamide

### Section

Antituberculosis medicines

Oral > Solid > dispersible tablet: 150 mg

Oral > Solid > tablet: 400 mg; 500 mg

### Indications

Tuberculosis

## Pyridostigmine

| Section                                                                                                                                                                                                                               | Indications       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Muscle relaxants (peripherally-acting) and cholinesterase inhibitors<br>Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)<br>Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide) | Myasthenia gravis |
| Medicines for myasthenia gravis<br>Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide)<br>Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)                                      | Myasthenia gravis |

## Pyridoxine

| Section                                                                                      | Indications                                                                      |
|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
| Vitamins and minerals<br>Oral > Solid > tablet: 25 mg (hydrochloride); 10 mg (hydrochloride) | Other specified polyneuropathy<br>Vitamin B6 deficiency<br>Sideroblastic anaemia |

## Pyrimethamine

| Section                                                                   | Indications   |
|---------------------------------------------------------------------------|---------------|
| Antipneumocystosis and antitoxoplasmosis medicines<br>Oral > Solid: 25 mg | Toxoplasmosis |

## Quetiapine

| Section                                                                                                                                                                                                                                                                                                                                   | Indications                                                                                     |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Medicines for psychotic disorders                                                                                                                                                                                                                                                                                                         | Therapeutic equivalent to risperidone for<br>Schizophrenia or other primary psychotic disorders |
| Medicines for bipolar disorders<br>Oral > Solid > tablet: 25 mg (immediate-release); 100 mg (immediate-release); 150 mg (immediate-release); 200 mg (immediate-release); 300 mg (immediate-release); 50 mg (modified-release); 150 mg (modified-release); 200 mg (modified-release); 300 mg (modified-release); 400 mg (modified-release) | Bipolar or related disorders                                                                    |

## Quinidine

### Section

Antiarrhythmic medicines

Oral > Solid: 200 mg (sulfate)

### Indications

Cardiac arrhythmia

## Quinine

### Section

Antimalarial medicines > Medicines for curative treatment

Parenteral > General injections > IV: 300 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion; 60 mg per mL in 2 mL ampoule (hydrochloride) solution for infusion

### Indications

Malaria due to *Plasmodium falciparum*

## Rabies vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against rabies

## Raltegravir

### Section

Antiretrovirals > Integrase inhibitors

Oral > Liquid: 100 mg granules for oral suspension

Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Ranibizumab

### Section

Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations

.

### Indications

Retinal venous occlusions

Diabetic macular oedema

Degenerative high myopia

Age related macular degeneration

## Ranitidine

### Section

Antiulcer medicines

Oral > Liquid: 75 mg per 5 mL (as hydrochloride)

Oral > Solid: 150 mg (as hydrochloride)

Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (as hydrochloride)

### Indications

Gastro-oesophageal reflux disease

Peptic ulcer, site unspecified

## Rasburicase

| Section                                                                                                                                                                | Indications           |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Supportive medicines<br>Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution | Tumour lysis syndrome |

## Ravidasvir

| Section                                                                                                        | Indications         |
|----------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 200 mg | Chronic hepatitis C |

## Ready to use therapeutic food

| Section                                                                                                                                                                                                    | Indications                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Therapeutic foods<br>Biscuit or paste of nutritional composition as determined by the UN joint statement on the community-based management of severe acute malnutrition and Codex alimentarius guidelines. | Acute malnutrition in infants, children or adolescents |

## Realgar-indigo naturalis formulation

| Section                                                                                    | Indications                                                  |
|--------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Cytotoxic medicines<br>Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg) | Acute myeloid leukaemia with recurrent genetic abnormalities |

## Red blood cells

| Section                                                             | Indications                                  |
|---------------------------------------------------------------------|----------------------------------------------|
| Blood and blood components<br>Parenteral > General injections > IV: | Blood transfusion without reported diagnosis |

## Resin-based composite (high-viscosity)

| Section                                                                                               | Indications   |
|-------------------------------------------------------------------------------------------------------|---------------|
| Dental medicines and preparations<br>Local > Topical > Other: Single-use capsule or multi-use syringe | Dental caries |

## Resin-based composite (low-viscosity)

| Section                                                                                                 | Indications   |
|---------------------------------------------------------------------------------------------------------|---------------|
| Dental medicines and preparations<br>Local > Topical > Other: Single-use applicator or multi-use bottle | Dental caries |

## Respiratory syncytial virus vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Retinol

### Section

#### Vitamins and minerals

Parenteral > General injections > IM: 50000 IU per mL in 2 mL ampoule or vial water-miscible (as palmitate)

Oral > Liquid: 100000 IU per mL (as palmitate or acetate)

Oral > Solid > capsule: 200000 IU (as palmitate or acetate) soft capsule; 50000 IU (as palmitate); 100000 IU (as palmitate or acetate) soft capsule

### Indications

Vitamin A deficiency

## Ribavirin

### Section

#### Medicines for hepatitis C > Other antivirals for hepatitis C

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

#### Other antivirals

Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution

Oral > Solid: 200 mg; 400 mg; 600 mg

### Indications

Chronic hepatitis C

Viral haemorrhagic fever, not elsewhere classified

## Ribociclib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to palbociclib for

Other specified malignant neoplasms of breast

## Riboflavin

### Section

#### Vitamins and minerals

Oral > Solid: 5 mg

### Indications

Vitamin B2 deficiency

## Rifabutin

### Section

Antituberculosis medicines

Oral > Solid: 150 mg

### Indications

Tuberculosis

## Rifampicin

### Section

Antituberculosis medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

Parenteral > General injections > IV: 600 mg in vial powder for injection

Antileprosy medicines

Oral > Liquid: 20 mg per mL

Oral > Solid: 150 mg; 300 mg

### Indications

Tuberculosis

Other specified tuberculosis

Leprosy

## Rifapentine

### Section

Antituberculosis medicines

Oral > Solid > tablet: 150 mg; 300 mg

Oral > Solid > dispersible tablet: 150 mg

### Indications

Tuberculosis

Latent tuberculosis

## Risdiplam

### Section

Medicines for neurological disorders

Oral > Liquid: 0.75 mg per mL powder for oral liquid

Oral > Solid > dispersible tablet: 5 mg

### Indications

Spinal muscular atrophy

## Risperidone

### Section

Medicines for psychotic disorders

Oral > Solid: 0.25 mg; 0.5 mg; 1 mg; 2 mg; 3 mg; 4 mg; 6 mg

Parenteral > General injections > IM:

### Indications

Schizophrenia or other primary psychotic disorders

Therapeutic equivalent to [paliperidone](#) for

Schizophrenia or other primary psychotic disorders

## Ritonavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Rituximab

### Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Medicines for multiple sclerosis

Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial

### Indications

Follicular lymphoma

Burkitt lymphoma including Burkitt leukaemia

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphoma, not otherwise specified

Multiple sclerosis

## Rivaroxaban

### Section

Medicines affecting coagulation

### Indications

Therapeutic equivalent to dabigatran for

Venous thromboembolism

Therapeutic equivalent to dabigatran for

Other specified atrial fibrillation

## Ropinirole

### Section

Antiseizure medicines

Oral > Solid: 0.25 mg immediate-release; 0.5 mg immediate-release; 1 mg immediate-release; 2 mg immediate-release; 3 mg immediate-release; 4 mg immediate-release; 5 mg immediate-release; 2 mg extended-release; 4 mg extended-release; 6 mg extended-release; 8 mg extended-release; 12 mg extended-release

### Indications

Parkinson disease

## Rotavirus vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Rubella vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against rubella alone

## Salbutamol

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Parenteral > General injections > IV: 500 µg per mL in 1 mL ampoule (as sulfate); 500 µg per mL in 5 mL ampoule (as sulfate)

Respiratory > Inhalation > solution: 100 µg per actuation in pressurized metered dose inhaler (as sulfate); 2.5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per 2.5 mL in 2.5 mL ampoule (as sulfate) for use in nebulizers; 5 mg per mL in multi-dose bottle (as sulfate) for use in nebulizers

### Indications

Chronic obstructive pulmonary disease

Asthma

## Salicylic acid

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Solution: 5%

### Indications

Seborrhoeic dermatitis

Psoriasis of unspecified type

Ichthyoses

## Saquinavir

### Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Selenium sulfide

### Section

Dermatological medicines > Antifungal medicines

Local > Topical > Suspension: 2% detergent-based

### Indications

Seborrhoeic dermatitis

Pityriasis versicolor

## Semaglutide

### Section

#### Hypoglycaemic agents

Parenteral > General injections > SC: 0.25 mg in pre-filled pen injection solution; 0.5 mg in pre-filled pen injection solution; 1 mg in pre-filled pen injection solution; 2 mg in pre-filled pen injection solution; 4 mg in pre-filled pen injection solution

Oral > Solid > tablet: 3 mg

Parenteral > General injections > SC: 0.68 mg per mL; 1.34 mg per mL; 2.68 mg per mL

### Indications

Obesity

Type 2 diabetes mellitus

## Senna

### Section

#### Medicines for other common symptoms in palliative care

Oral > Liquid: 7.5 mg per 5 mL oral liquid

#### Laxatives

Oral > Solid: 7.5 mg (sennosides) (or traditional dosage forms)

### Indications

Palliative care

Constipation

## Sevoflurane

### Section

#### General anaesthetics and oxygen > Inhalational medicines

Respiratory > Inhalation > liquid:

### Indications

Anaesthetics and therapeutic gases

## Silver diamine fluoride

### Section

#### Dental medicines and preparations

Local > Dental > Solution: 38% w/v

### Indications

Dental caries

## Silver nitrate

### Section

#### Ophthalmological preparations > Anti-infective agents

Local > Ophthalmological > Solution (eye drops): 1%

### Indications

Neonatal conjunctivitis or dacryocystitis

## Silver sulfadiazine

### Section

#### Dermatological medicines > Anti-infective medicines

Local > Topical > Cream: 1%

### Indications

Burns

## Simeprevir

### Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations  
Oral > Solid: 150 mg

### Indications

Chronic hepatitis C

## Simvastatin

### Section

Lipid-lowering agents  
Oral > Solid: 5 mg; 10 mg; 20 mg; 40 mg

Medicines for endocrine disorders  
Oral > Solid: 20 mg

### Indications

Mixed hyperlipidaemia

Coronary atherosclerosis

Polycystic ovary syndrome

## Smallpox vaccine

### Section

Immunologicals > Vaccines  
All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Snake antivenom

### Section

Immunologicals > Sera, immunoglobulins and monoclonal antibodies  
.

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium calcium edetate

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 200 mg per mL in 5 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium chloride

### Section

Solutions correcting water, electrolyte and acid-base disturbances > Parenteral  
Parenteral > General injections > IV: 0.9% isotonic (equivalent to Na<sup>+</sup> 154 mmol/L and Cl<sup>-</sup> 154 mmol/L)

### Indications

Other specified disorders of fluid, electrolyte or acid-base balance

## Sodium hyaluronate

### Section

Ophthalmological preparations

### Indications

Therapeutic equivalent to [hypromellose](#) for

Keratoconjunctivitis sicca

## Sodium hydrogen carbonate

### Section

Solutions correcting water, electrolyte and acid-base disturbances >  
Parenteral

Parenteral > General injections > IV: 1.4% isotonic (equivalent to Na<sup>+</sup> 167 mmol/L and HCO<sub>3</sub><sup>-</sup> 167 mmol/L); 8.4% in 10 mL ampoule (equivalent to Na<sup>+</sup> 1000 mmol/L and HCO<sub>3</sub><sup>-</sup> 1000 mmol/L)

### Indications

Acidosis

## Sodium nitrite

### Section

Antidotes and other substances used in poisonings > Specific  
Parenteral > General injections > IV: 30 mg per mL in 10 mL ampoule

### Indications

Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified

## Sodium nitroprusside

### Section

Antihypertensive medicines  
Parenteral > General injections > IV: 50 mg in ampoule powder for infusion

### Indications

Hypertensive crisis

## Sodium stibogluconate

### Section

Antileishmaniasis medicines  
Parenteral > General injections > unspecified: 100 mg per mL in 30 mL vial

### Indications

Visceral leishmaniasis

Mucocutaneous leishmaniasis

Cutaneous leishmaniasis

## Sodium thiosulfate

| Section                                                                                                                              | Indications                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Dermatological medicines > Antifungal medicines<br>Local > Topical > Solution: 15%                                                   | Pityriasis versicolor                                                                                             |
| Antidotes and other substances used in poisonings > Specific<br>Parenteral > General injections > IV: 250 mg per mL in 50 mL ampoule | Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified |

## Sofosbuvir

| Section                                                                                                                                                             | Indications         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 200 mg; 400 mg<br>Oral > Solid > granules: 200 mg in sachet | Chronic hepatitis C |

## Sofosbuvir + velpatasvir

| Section                                                                                                                                                                                                                  | Indications         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations<br>Oral > Solid > tablet: 200 mg + 50 mg; 400 mg + 100 mg<br>Oral > Solid > granules: 150 mg + 37.5 mg in sachet; 200 mg + 50 mg in sachet | Chronic hepatitis C |

## Somatropin

| Section                                                                                                                                          | Indications                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| Medicines for endocrine disorders<br>Parenteral > General injections > SC: 5 mg in cartridge powder for injection; 5 mg per mL in 2 mL cartridge | Hypoglycaemia without associated diabetes |

## Spectinomycin

| Section                                                                                                                        | Indications                                                  |
|--------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
| Access group antibiotics<br>Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection | Second choice<br>Gonococcal infection                        |
|                                                                                                                                | Other indications<br>Bacterial infection of unspecified site |

## Spironolactone

| Section                                                                             | Indications       |
|-------------------------------------------------------------------------------------|-------------------|
| Medicines used in heart failure<br>Oral > Solid > tablet: 25 mg                     | Heart failure     |
| Diuretics<br>Oral > Liquid: 25 mg per 5 mL<br>Oral > Solid > tablet: 25 mg; 12.5 mg | Oedema<br>Ascites |

## Stavudine

| Section                                                                                                                                                                | Indications                                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors<br>Oral > Liquid: 5 mg per 5 mL powder for oral solution<br>Oral > Solid: 15 mg; 20 mg; 30 mg | Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified |

## Streptokinase

| Section                                                                                                     | Indications                 |
|-------------------------------------------------------------------------------------------------------------|-----------------------------|
| Thrombolytic medicines<br>Parenteral > General injections > IV: 1.5 million IU in vial powder for injection | Acute myocardial infarction |

## Streptomycin (injection)

| Section                                                                                                           | Indications                                     |
|-------------------------------------------------------------------------------------------------------------------|-------------------------------------------------|
| Antituberculosis medicines<br>Parenteral > General injections > IV: 1 g powder for injection (as sulfate) as vial | Multi-drug resistant Mycobacterium tuberculosis |

## Succimer

| Section                                                                              | Indications                                                                                                       |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Antidotes and other substances used in poisonings > Specific<br>Oral > Solid: 100 mg | Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified |

## Sulfacetamide

| Section                                                                                                         | Indications                    |
|-----------------------------------------------------------------------------------------------------------------|--------------------------------|
| Ophthalmological preparations > Anti-infective agents<br>Local > Ophthalmological > Ointment: 10% (sodium salt) | Other specified conjunctivitis |

## Sulfadiazine

| Section                                                                                                                                 | Indications                             |
|-----------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Antipneumocystosis and antitoxoplasmosis medicines<br>Oral > Solid: 500 mg                                                              | Toxoplasmosis                           |
| Anti-infective medicines<br>Oral > Solid: 500 mg<br>Parenteral > General injections > unspecified: 250 mg in 4 mL ampoule (sodium salt) | Bacterial infection of unspecified site |

## Sulfadimidine

| Section                                                                                                                                                                | Indications                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Anti-infective medicines<br>Oral > Liquid: 500 mg per 5 mL<br>Oral > Solid: 500 mg<br>Parenteral > General injections > unspecified: 1 g in 3 mL ampoule (sodium salt) | Bacterial infection of unspecified site |

## Sulfadoxine + pyrimethamine

| Section                                                                                                              | Indications                                                             |
|----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Antimalarial medicines > For chemoprevention<br>Oral > Solid: 500 mg + 25 mg tablet                                  | Malaria due to Plasmodium falciparum                                    |
| Antimalarial medicines > Medicines for curative treatment<br>Oral > Solid: 500 mg + 25 mg tablet                     | Malaria due to Plasmodium falciparum<br>Malaria due to Plasmodium vivax |
| Antimalarial medicines > Medicines for chemoprevention<br>Oral > Solid > dispersible tablet: 250 mg + 12.5 mg tablet | Malaria                                                                 |

## Sulfamethoxazole + trimethoprim

| Section                                                                                                                                                                                                                                                                                                                                                                         | Indications                                                                                                                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Access group antibiotics</b><br>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule<br>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid<br>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet<br>Oral > Solid > dispersible tablet: 100 mg + 20 mg                           | <b>First choice</b><br>Infectious cystitis<br><b>Second choice</b><br>Infectious gastroenteritis or colitis without specification of infectious agent<br><b>Other indications</b><br>Bacterial infection of unspecified site<br>Pneumocystosis |
| <b>Antipneumocystosis and antitoxoplasmosis medicines</b><br>Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule<br>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid<br>Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet<br>Oral > Solid > dispersible tablet: 100 mg + 20 mg |                                                                                                                                                                                                                                                |

## Sulfasalazine

| Section                                                                                                                                                | Indications                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------|
| <b>Disease-modifying anti-rheumatic drugs (DMARDs)</b><br>Oral > Solid: 500 mg                                                                         | Rheumatoid arthritis, serology unspecified |
| <b>Anti-inflammatory medicines</b><br>Oral > Solid: 500 mg<br>Local > Rectal > Suppository: 500 mg<br>Local > Rectal > Retention enema: 3 g per 100 mL | Crohn disease site<br>Ulcerative colitis   |

## Sumatriptan

| Section                                                                                                                                                 | Indications                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| <b>Medicines for acute migraine attacks</b><br>Oral > Solid > tablet: 50 mg                                                                             | Migraine                          |
| <b>Medicines for cluster headache</b><br>Parenteral > General injections > SC: 6 mg per 0.5 mL in pre-filled pen; 6 mg per 0.5 mL in pre-filled syringe | Trigeminal autonomic cephalalgias |

## Sunscreen, broad-spectrum

### Section

#### Dermatological medicines

Topical cream, lotion, gel, ointment, spray with sun protection factor  $\geq$  50.

#### Dermatological medicines > Sunscreens

Topical:

Therapeutic broad-spectrum sunscreens should contain proven active ingredients in appropriate amounts to absorb or filter UVA and UVB radiation, and have a high sun protection factor (SPF).

### Indications

Xeroderma pigmentosum

Albinism or other specified genetically-determined hypomelanotic disorders

## Suramin sodium

### Section

#### Antifilarials

Parenteral > General injections > IV: 1 g in vial

#### Medicines for the treatment of 1st stage African trypanosomiasis

Parenteral > General injections > IV: 1 g in vial

### Indications

Filariasis

Rhodesiense trypanosomiasis

## Suxamethonium

### Section

#### Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 50 mg per mL in 2 mL ampoule (chloride)

### Indications

Muscle relaxants

## Tacalcitol

### Section

#### Dermatological medicines > Medicines affecting skin differentiation and proliferation

### Indications

Therapeutic equivalent to [calcipotriol](#) for

Psoriasis of unspecified type

## Tacrolimus

### Section

#### Immunomodulators for non-malignant disease

Parenteral > General injections > IV: 5 mg per mL in 1 mL vial

Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension

Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

### Indications

Failure or rejection of transplanted organs or tissues

## Tamoxifen

| Section                                                                           | Indications                                                                                       |
|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Hormones and antihormones<br>Oral > Solid: 10 mg (as citrate); 20 mg (as citrate) | <div>Other specified malignant neoplasms of breast</div> <div>Malignant neoplasms of breast</div> |

## Tedizolid

| Section                   | Indications                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Reserve group antibiotics | <div>Therapeutic equivalent to <b>linezolid</b> for</div> <div>Methicillin resistant <i>Staphylococcus aureus</i></div> <div>Therapeutic equivalent to <b>linezolid</b> for</div> <div>Vancomycin resistant <i>Staphylococcus aureus</i></div> <div>Therapeutic equivalent to <b>linezolid</b> for</div> <div>Vancomycin resistant <i>Enterococcus</i></div> |

## Telmisartan + amlodipine

| Section                                                                               | Indications                       |
|---------------------------------------------------------------------------------------|-----------------------------------|
| Antihypertensive medicines<br>Oral > Solid: 40 mg + 5 mg; 80 mg + 5 mg; 80 mg + 10 mg | <div>Essential hypertension</div> |

## Telmisartan + hydrochlorothiazide

| Section                                                                                     | Indications                       |
|---------------------------------------------------------------------------------------------|-----------------------------------|
| Antihypertensive medicines<br>Oral > Solid: 40 mg + 12.5 mg; 80 mg + 12.5 mg; 80 mg + 25 mg | <div>Essential hypertension</div> |

## Temozolomide

| Section                                                                                                                                                                 | Indications                                                                                                                                                                                                                            |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cytotoxic medicines<br>Parenteral > General injections > IV: 100 mg in vial powder for injection<br>Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg | <div>Ewing sarcoma of bone and articular cartilage of unspecified sites</div> <div>Other specified gliomas of brain</div> <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Neuroblastoma, NOS</div> |

## Tenofovir alafenamide

### Section

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 25 mg

### Indications

Chronic hepatitis B

## Tenofovir disoproxil fumarate

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors  
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Chronic hepatitis B

## Terbinafine

### Section

Dermatological medicines > Antifungal medicines  
Local > Topical > Cream: 1% terbinafine hydrochloride  
Local > Topical > Ointment: 1% terbinafine hydrochloride

### Indications

Fungal infection of the skin

## Terbutaline

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to salbutamol for

Chronic obstructive pulmonary disease

Therapeutic equivalent to salbutamol for

Asthma

## Terizidone

### Section

Antituberculosis medicines

### Indications

Therapeutic equivalent to cycloserine for

Multi-drug resistant Mycobacterium tuberculosis

## Testosterone

| Section                                                                                                     | Indications                                              |
|-------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| <a href="#">Androgens</a><br>Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule (enantate) | Testicular dysfunction or testosterone-related disorders |

## Tetanus antitoxin

| Section                                                                                                                                    | Indications |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| <a href="#">Immunologicals</a> > Sera, immunoglobulins and monoclonal antibodies<br>Parenteral > General injections > IM: 50000 IU in vial | Tetanus     |

## Tetanus vaccine

| Section                                                                                                                      | Indications                                 |
|------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|
| <a href="#">Immunologicals</a> > Vaccines<br>All vaccines should comply with the WHO requirements for biological substances. | Need for immunization against tetanus alone |

## Tetracaine

| Section                                                                                                                                     | Indications        |
|---------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| <a href="#">Ophthalmological preparations</a> > Local anaesthetics<br>Local > Ophthalmological > Solution (eye drops): 0.5% (hydrochloride) | Local anaesthetics |

## Tetracycline

| Section                                                                                                                                       | Indications                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|
| <a href="#">Access group antibiotics</a><br>Oral > Solid: 250 mg (hydrochloride)                                                              | Bacterial infection of unspecified site   |
| <a href="#">Ophthalmological preparations</a> > Anti-infective agents<br>Local > Ophthalmological > Ointment: 1% (tetracycline hydrochloride) | Neonatal conjunctivitis or dacryocystitis |
|                                                                                                                                               | Other specified conjunctivitis            |
|                                                                                                                                               | Infectious keratitis                      |
|                                                                                                                                               | Infectious blepharitis                    |
|                                                                                                                                               | Trachoma                                  |

## Thalidomide

| Section                                                 | Indications         |
|---------------------------------------------------------|---------------------|
| <a href="#">Immunomodulators</a><br>Oral > Solid: 50 mg | Plasma cell myeloma |

## Thiamine

### Section

Vitamins and minerals

Parenteral > General injections > IV: 50 mg per mL in ampoule or vial (hydrochloride)

Oral > Solid > tablet: 50 mg (hydrochloride)

### Indications

Vitamin B1 deficiency

## Thiopental

### Section

General anaesthetics and oxygen > Injectable medicines

### Indications

Therapeutic equivalent to propofol for

Anaesthetics and therapeutic gases

## Ticagrelor

### Section

Anti-platelet medicines

Oral > Solid > tablet: 60 mg; 90 mg

### Indications

Acute ischaemic heart disease

Presence of coronary angioplasty implant or graft

## Tick-borne encephalitis vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against arthropod-borne viral encephalitis

## Tigecycline

### Section

Reserve group antibiotics

Parenteral > General injections > IV: 50 mg in vial powder for injection

### Indications

Other specified bacterial diseases

## Timolol

### Section

Ophthalmological preparations > Miotics and antiglaucoma medicines

Local > Ophthalmological > Solution (eye drops): 0.25% (hydrogen maleate); 0.5% (hydrogen maleate)

### Indications

Primary open-angle glaucoma

Ocular hypertension

## Tinidazole

### Section

Antiamoebic and anti giardiasis medicines

### Indications

Therapeutic equivalent to [metronidazole](#) for

Amoebiasis

## Tioguanine

### Section

Cytotoxic medicines

Oral > Solid: 40 mg

### Indications

Lymphoid leukaemia, not elsewhere classified

## Tiotropium bromide

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

Respiratory > Inhalation > powder: 18 µg in capsule

Respiratory > Inhalation > solution: 1.25 µg per actuation in soft mist inhaler; 2.5 µg per actuation in soft mist inhaler

### Indications

Chronic obstructive pulmonary disease

## Tirzepatide

### Section

Hypoglycaemic agents

### Indications

Therapeutic equivalent to [semaglutide](#) for

Obesity

Therapeutic equivalent to [semaglutide](#) for

Type 2 diabetes mellitus

## Tisagenlecleucel

### Section

Antineoplastics and supportive medicines

### Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for

Diffuse large B-cell lymphomas

## Tislelizumab

| Section                                                                                      | Indications                                             |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------|
| Immunomodulators                                                                             | Malignant neoplasms of urinary tract                    |
| Parenteral > General injections > IV: 100 mg per 10 mL                                       | Hodgkin lymphoma                                        |
| Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion | Other specified malignant neoplasms of bronchus or lung |
| Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion | Squamous cell carcinoma of oesophagus                   |

## Tobramycin

| Section                                               | Indications                              |
|-------------------------------------------------------|------------------------------------------|
| Ophthalmological preparations > Anti-infective agents | Therapeutic equivalent to gentamicin for |
|                                                       | Other specified conjunctivitis           |
|                                                       | Therapeutic equivalent to gentamicin for |
|                                                       | Infectious blepharitis                   |

## Tocilizumab

| Section                                                                                                          | Indications                 |
|------------------------------------------------------------------------------------------------------------------|-----------------------------|
| Medicines for juvenile joint diseases                                                                            | Juvenile systemic arthritis |
| Parenteral > General injections > IV: 80 mg per 4 mL in vial; 200 mg per 10 mL in vial; 400 mg per 20 mL in vial |                             |
| Parenteral > General injections > SC: 162 mg per 0.9 mL in pre-filled syringe                                    |                             |

## Tolbutamide

| Section                   | Indications              |
|---------------------------|--------------------------|
| Oral hypoglycaemic agents | Type 2 diabetes mellitus |
| Oral > Solid: 500 mg      |                          |

## Torase mide

| Section                         | Indications                                                                                                          |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------|
| Medicines used in heart failure | Therapeutic equivalent to furosemide for<br>Heart failure                                                            |
| Diuretics                       | Therapeutic equivalent to furosemide for<br>Anuria or oliguria<br>Therapeutic equivalent to furosemide for<br>Oedema |

## Toripalimab

| Section                                                                           | Indications                                                                 |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------|
| Immunomodulators<br>Parenteral > General injections > IV: 240 mg per 6 mL in vial | Malignant neoplasms of nasopharynx<br>Squamous cell carcinoma of oesophagus |

## Tramad ol

| Section                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Indications         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| Opioid analgesics<br>Oral > Liquid: 100 mg per mL (hydrochloride)<br>Oral > Solid: 50 mg (hydrochloride) immediate release; 50 mg (hydrochloride) controlled release; 100 mg (hydrochloride) controlled release; 150 mg (hydrochloride) controlled release; 200 mg (hydrochloride) controlled release; 300 mg (hydrochloride) controlled release; 400 mg (hydrochloride) controlled release<br>Parenteral > General injections > unspecified: 50 mg per mL in 2 mL ampoule (hydrochloride) | Chronic cancer pain |

## Trametinib

| Section                                          | Indications                      |
|--------------------------------------------------|----------------------------------|
| Targeted therapies<br>Oral > Solid: 0.5 mg; 2 mg | Other specified melanoma of skin |

## Tranexamic acid

| Section                                                                                                            | Indications                           |
|--------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Medicines affecting coagulation<br>Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule            | Haemorrhage, not elsewhere classified |
| Other medicines administered to the mother<br>Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule | Postpartum haemorrhage                |

## Trastuzumab

| Section                                                                                                                                                                  | Indications                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Targeted therapies<br>Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection | Carcinoma of breast, specialised type |

## Trastuzumab emtansine

| Section                                                                                                                              | Indications                           |
|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|
| Targeted therapies<br>Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection | Carcinoma of breast, specialised type |

## Tremelimumab

| Section                                                                                                                                                                                | Indications                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Immunomodulators<br>Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion | Hepatocellular carcinoma of liver<br>Other specified malignant neoplasms of bronchus or lung |

## Triamcinolone hexacetonide

| Section                                                                                                               | Indications                   |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------------|
| Medicines for juvenile joint diseases<br>Parenteral > Locoregional injections > Intra-articular: 20 mg per mL in vial | Juvenile idiopathic arthritis |

## Triclabendazole

| Section                                                                                      | Indications                    |
|----------------------------------------------------------------------------------------------|--------------------------------|
| Antischistosomes and other antitremitode medicines<br>Oral > Solid > tablet: 250 mg (scored) | Paragonimiasis<br>Fascioliasis |

## Trihexyphenidyl

### Section

Antiseizure medicines

Oral > Solid: 2 mg (hydrochloride); 5 mg (hydrochloride)

Medicines for parkinsonism

### Indications

Parkinson disease

Therapeutic equivalent to [biperiden](#) for

Parkinson disease

## Trimethoprim

### Section

Access group antibiotics

Oral > Liquid: 50 mg per mL

Oral > Solid: 100 mg; 200 mg

### Indications

First choice

Infectious cystitis

## Triptorelin

### Section

Hormones and antihormones

### Indications

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuporelin](#) for

Malignant neoplasms of prostate

## Tropicamide

### Section

Diagnostic agents > Ophthalmic medicines

Local > Ophthalmological > Solution (eye drops): 0.5%

### Indications

Cycloplegic drug

## Tropisetron

### Section

Medicines for other common symptoms in palliative care

### Indications

Therapeutic equivalent to [ondansetron](#) for

Palliative care

Antiemetic medicines

Therapeutic equivalent to [ondansetron](#) for

Nausea or vomiting

## Tuberculin, purified protein derivative

### Section

Immunologicals > Diagnostic agents

Parenteral > Locoregional injections > Intradermal:

### Indications

Mycobacterial diseases

## Tubocurarine

### Section

Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 1.5 mL ampoule (tubocurarine chloride)

### Indications

Muscle relaxants

## Typhoid vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against typhoid-paratyphoid alone

## Ulipristal

### Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

### Indications

Contact with health services for postcoital contraception

## Umeclidinium

### Section

Antiasthmatic and medicines for chronic obstructive pulmonary disease

### Indications

Therapeutic equivalent to tiotropium bromide for

Chronic obstructive pulmonary disease

## Urea

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Local > Topical > Cream: 10%; 5%

Local > Topical > Ointment: 10%; 5%

Dermatological medicines > Moisturizers

Local > Topical > Cream: 5 per %

### Indications

Xerosis cutis or asteatosis

Atopic eczema

## Ustekinumab

### Section

Dermatological medicines > Medicines affecting skin differentiation and proliferation

Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen

### Indications

Psoriasis of unspecified type

## Valaciclovir

### Section

Antiherpes medicines

Medicines for viral central nervous system infections

### Indications

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Therapeutic equivalent to [aciclovir](#) for

Herpes simplex infections

Therapeutic equivalent to [aciclovir](#) for

Zoster

Therapeutic equivalent to [aciclovir](#) for

Varicella

## Valganciclovir

### Section

Other antivirals

Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution

Oral > Solid > tablet: 450 mg (as hydrochloride)

### Indications

Cytomegaloviral retinitis

## Valproic acid (sodium valproate)

### Section

#### Medicines for bipolar disorders

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated)

#### Antiseizure medicines

Oral > Liquid: 200 mg per 5 mL

Oral > Solid: 200 mg tablet (enteric-coated); 500 mg tablet (enteric-coated); 100 mg tablet (crushable)

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 3 mL ampoule

### Indications

Bipolar or related disorders

Epilepsy or seizures

Status epilepticus

## Valsartan + amlodipine + hydrochlorothiazide

### Section

#### Antihypertensive medicines

Oral > Solid > dosage form: 160 mg + 5 mg + 12.5 mg; 160 mg + 5 mg + 25 mg; 160 mg + 10 mg + 12.5 mg; 160 mg + 10 mg + 25 mg; 320 mg + 10 mg + 25 mg

### Indications

Essential hypertension

## Vancomycin

### Section

#### Watch group antibiotics

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection

Oral > Solid > capsule: 125 mg (as hydrochloride); 250 mg (as hydrochloride)

Parenteral > General injections > IV: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

Parenteral > Locoregional injections > Intravitreal: 250 mg in vial (as hydrochloride) powder for injection; 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection

### Indications

#### First choice

Necrotising fasciitis

co-prescribed with ceftazidime

Endophthalmitis

co-prescribed with ceftriaxone

Endophthalmitis

#### Second choice

Neutropenia (high-risk)

Intestinal infections due to *Clostridioides difficile*

#### Other indications

Methicillin resistant *Staphylococcus aureus*

## Varenicline

### Section

#### Medicines for nicotine use disorders

Oral > Solid: 0.5 mg; 1 mg

### Indications

Nicotine dependence

## Varicella vaccine

### Section

#### Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Vecuronium

### Section

#### Muscle relaxants (peripherally-acting) and cholinesterase inhibitors

Parenteral > General injections > IV: 10 mg in vial powder for injection (vecuronium bromide)

### Indications

Muscle relaxants

## Vemurafenib

### Section

#### Targeted therapies

### Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

## Verapamil

### Section

#### Antiarrhythmic medicines

Parenteral > General injections > IV: 2.5 mg per mL in 2 mL ampoule (hydrochloride)

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

#### Antianginal medicines

Oral > Solid: 40 mg (hydrochloride); 80 mg (hydrochloride)

#### Medicines for cluster headache

Oral > Solid > tablet: 120 mg (hydrochloride) (immediate-release); 40 mg (hydrochloride) (immediate-release); 80 mg (hydrochloride) (immediate-release); 120 mg (hydrochloride) (extended-release); 180 mg (hydrochloride) (extended-release); 240 mg (hydrochloride) (extended-release)

### Indications

Supraventricular tachyarrhythmia

Angina pectoris

Trigeminal autonomic cephalalgias

## Vinblastine

| Section                                                                                                                                                                                                                             | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)<br>Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate) | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Other specified gliomas of brain</div> <div>Kaposi sarcoma of unspecified primary site</div> <div>Hodgkin lymphoma</div> <div>Other specified malignant neoplasms of the ovary</div> <div>Germ cell tumour of testis</div> <div>Anaplastic large cell lymphoma, ALK-positive</div> <div>Anaplastic large cell lymphoma, ALK-negative</div> <div>Langerhans cell histiocytosis</div> |

## Vincristine

| Section                                                                                                                                                                                                                                                                                                                                            | Indications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)<br>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate) | <div>Unspecified malignant neoplasms of ill-defined or unspecified sites</div> <div>Other specified gliomas of brain</div> <div>Malignant trophoblastic neoplasms of placenta</div> <div>Follicular lymphoma</div> <div>Kaposi sarcoma of unspecified primary site</div> <div>Rhabdomyosarcoma primary site</div> <div>Hodgkin lymphoma</div> <div>Retinoblastoma</div> <div>Malignant neoplasms of kidney, except renal pelvis</div> <div>Ewing sarcoma of bone and articular cartilage of unspecified sites</div> <div>Langerhans cell histiocytosis</div> <div>Lymphoid leukaemia, not elsewhere classified</div> <div>Burkitt lymphoma including Burkitt leukaemia</div> <div>Diffuse large B-cell lymphoma, not otherwise specified</div> |

## Vinorelbine

| Section                                                                                                                                                                                                                                                               | Indications                                                                                                                                                          |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Cytotoxic medicines</b><br>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial<br>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial<br>Oral > Solid > capsule: 20 mg; 30 mg; 80 mg | <div>Other specified malignant neoplasms of bronchus or lung</div> <div>Other specified malignant neoplasms of breast</div> <div>Rhabdomyosarcoma primary site</div> |

## Voriconazole

| Section                                                                                                                                                                                                     | Indications                                                                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| <b>Antifungal medicines</b><br>Parenteral > General injections > IV: 200 mg in vial powder for injection<br>Oral > Liquid: 40 mg per mL powder for oral liquid<br>Oral > Solid: 50 mg tablet; 200 mg tablet | <div>Chronic pulmonary aspergillosis</div> <div>Invasive aspergillosis</div> |

## Warfarin

| Section                                                                                                                                                                                                                                                                                                                                      | Indications                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Medicines affecting coagulation</b><br>Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)<br>Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium) | <div>Other specified diseases of arteries or arterioles</div> <div>Venous thromboembolism</div> <div>Cerebral ischaemic stroke due to embolic occlusion</div> <div>Atrial fibrillation</div> |

## Water for injection

| Section                                                                                                                                                                                  | Indications                                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| <b>Solutions correcting water, electrolyte and acid-base disturbances &gt; Miscellaneous</b><br>Parenteral > General injections > unspecified: 2 mL ampoule; 5 mL ampoule; 10 mL ampoule | <div>Unspecified appropriateness of dosing or administration without injury or harm</div> |

## Whole blood

| Section                                                                    | Indications                                             |
|----------------------------------------------------------------------------|---------------------------------------------------------|
| <b>Blood and blood components</b><br>Parenteral > General injections > IV: | <div>Blood transfusion without reported diagnosis</div> |

## Xylometazoline

### Section

Ear, nose and throat medicines [c]

Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL

Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL

### Indications

Nasal congestion

## Yellow fever vaccine

### Section

Immunologicals > Vaccines

All vaccines should comply with the WHO requirements for biological substances.

### Indications

Need for immunization against certain single viral diseases

## Zanubrutinib

### Section

Targeted therapies

Oral > Solid: 80 mg

Oral > Solid > capsule: 80 mg

### Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to ibrutinib for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

## Zidovudine

### Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion

Oral > Liquid: 50 mg per 5 mL

Oral > Solid > tablet: 300 mg

Oral > Solid > capsule: 250 mg

### Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

## Zinc sulfate

### Section

Medicines for diarrhoea

Oral > Solid > dispersible tablet: 20 mg (scored)

### Indications

Diarrhoea

## Zoledronic acid

### Section

#### Supportive medicines

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

#### Medicines for endocrine disorders

Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

### Indications

Malignant neoplasm metastasis in bone or bone marrow

Osteogenesis imperfecta

## Zuclopenthixol decanoate

### Section

#### Medicines for psychotic disorders

### Indications

Therapeutic equivalent to fluphenazine for

Schizophrenia or other primary psychotic disorders